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1 Introduction 
1.1 Lung cancer 
1.1.1 Overview 
Lung cancer is the leading cause of cancer deaths worldwide with a European age-standardized 
mean five-year survival of 13% (Angelis et al. 2014). Histological classification of lung cancer is 
the cornerstone for diagnosis, treatment and prognosis. The vast majority of lung cancers are 
non-small-cell lung cancers (NSCLC) which account for approximately 80%, with the remain-
der being mostly small cell lung cancers (SCLC) (Oser et al. 2015). The emerging use of im-
munohistochemistry techniques and the integration of molecular testing have played a signifi-
cant role in the new World Health Organization (WHO) classification of lung cancer in 2015. 
This has helped with pathological subtyping of NSCLC depending on certain histological and 
molecular features, and started a new era of disease-specific therapy (Travis et al. 2015). 
NSCLC is further classified into adenocarcinoma, which is the most common type of lung 
cancer (about 40%), and squamous cell carcinoma (SCC), which arises from epithelial cells 
lining the airways as well as alveolar cells type II. The last and least common type of NSCLC is 
undifferentiated large cell carcinoma, which lacks the morphological and immunohistochemi-
cal features of the other types. (Zappa and Mousa 2016) 
Small cell lung cancer (SCLC) accounts for nearly 15% of lung cancer cases. It is characterized 
by a rapid progressive course and typically affects older men with a heavy smoking history. 
Among lung cancers it is the most common cause of paraneoplastic syndrome, even though it 
appears to be very sensitive to cytotoxic chemotherapy  (van Meerbeeck et al. 2011). 
Due to the lack of effective screening, most lung cancer patients are diagnosed in late disease 
stages. Lung cancer-suspected patients are usually symptomatic patients with risk factors. Pa-
tients usually present with nonspecific symptoms of cough and shortness of breath. Symptoms 
can also be triggered by the local spread of the primary tumor, metastatic lesions or parane-
oplastic syndrome (Latimer 2018). 
1.1.2 Epidemiology 
Lung cancer is the most common type of cancer worldwide, contributing to 12.4% of all newly 
diagnosed cancer cases, and is by far the first leading cause (17.6%) of cancer deaths. The inci-
dence in developing countries has been increasing in the last two decades and has almost 
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equalized its incidence in the world’s developed countries. Due to lifestyle changes and the 
increase of tobacco consumption among women, since 1985, the incidence has increased by 
76% in women versus 44% in men with an ongoing male predominance, and with about a 
1.5:1 male to female incidence ratio (Dela Cruz et al. 2011). 
In Germany, lung cancer is the second most diagnosed cancer in men and the third in women 
and still the most common cause of cancer deaths in men (24.4% of all cancer deaths), and the 
second most common cause of cancer deaths in women (15.4%) (Robert Koch-Institute). 
  
Figure 1:Pie charts presenting the numbers of cancer cases in Germany as a percentage based on tumor 
site and gender according to the German cancer registry 2014 (Robert Koch-Institute).  
Unlike in men, since 1998,  the incidence of lung cancer and its related mortality have been 
rising continuously in German women. This can be explained by the change of smoking habits 
in German society. According to the German cancer registry (2014), the lung cancer five-year 
survival was 20% in women versus 15% in men (Robert Koch-Institute). 
1.1.3 Risk factors 
More than 90% of lung cancer cases can be attributed to tobacco smoke (Dela Cruz et al. 
2011). Smoking causes about 5.4 million deaths per annum around the globe. Notwithstanding, 
it remains a preventable cause of death (World Health Organization, 2008). The chance of 
developing lung cancer within a lifetime due to smoking is 20-fold higher than in those who 
have never smoked. Cigarette smoke contains numerous carcinogens and mutagens (Dela Cruz 
et al. 2011). Lung cancer in never smokers has been an interesting topic in the last three dec-
ades. Several large cohort studies with patients from different ethnicities concluded that the 
majority of never-smoker lung cancer patients were females with adenocarcinoma (Sun et al. 
2007). 
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The trend of using low tar or filtered cigarettes did not appear to lower the harm caused by 
smoking. On the contrary, it has been connected to increased rates of lung adenocarcinoma by 
increasing the volume of inhaled smoke and consequently increasing toxin distribution through 
the lungs. This was concluded in 2014 in the Surgeon General’s Report in the Health Conse-
quences of Smoking (Song et al. 2017). 
Occupational lung cancer was recognized in the eighteenth century. Schneeberg lung disease 
was the first name given for radon-induced lung cancer. In 1860, two German physicians, 
Härting and Hesse, described the incidence of a fatal lung disease in miners who were working 
in Schneeberg Mountains in the so called kingdom of Saxony. They succeeded in performing 
autopsies on some dead workers and they sent these to the pathological institute of Leipzig 
University. The autopsies recognized this as a malignant disease. Härting and Hesse were the 
first who described occupational lung cancer (Schüttmann 1993). Radon is a noble radioactive 
gas that results from the normal decaying chain of Uranium. It is a human carcinogen with a 
dose-dependent effect. Nowadays, it is recognized to be the second leading cause of lung can-
cer. Radon exposure and smoking have a synergetic effect. The mortality rates of cancer pa-
tients were higher in smokers who had a confirmed exposure to radon (Lantz et al. 2013). 
Other risk factors include air pollution. An analysis of 17 cohort studies from European coun-
tries concluded a significant association between exposure to particle matters in the air and the 
incidence of lung cancer in Europe (Raaschou-Nielsen et al. 2013). 
Some studies suggest that asbestos fibers can generate up-regulated signaling pathways which 
are responsible for cancer development and therapy resistance. This effect is thought to be 
mediated by the direct interaction between asbestos fibers and cell surface receptors or by as-
bestos-induced reactive oxygen species (Heintz et al. 2010). 
A pooled analysis on 24,607 cases and 81,829 controls demonstrated a higher risk of lung can-
cer in patients with previous lung disease (chronic bronchitis, pneumonia, emphysema and 
tuberculosis). Inflammation plays a significant role in lung cancer development by increasing 
genetic mutations, anti-apoptotic signaling and angiogenesis (Brenner et al. 2012). 
1.1.4 Approach and Staging 
Patients with lung cancer typically present with non-specific symptoms at the time of diagno-
sis. Less frequently, patients are referred for further investigation of a suspicious accidental 
finding. Diagnosis of lung cancer is a comprehensive work up that includes conventional test-
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ing and invasive approaches that aim to establish a definitive diagnosis and to evaluate a pa-
tient’s functional status and relevant comorbidities. The initial work up involves clinical history 
and examination, reviewing of possible risk factors, and conventional imaging (Ham-
merschmidt and Wirtz 2009). A plain chest radiograph is a simple accessible informative test 
with a negligible radiation exposure. It is a sensible primary test for patients with non-specific 
respiratory symptoms (Rogers 2010). 
Other diagnostic modalities could include contrast-enhanced or native computer tomography 
(CT) or magnetic resonance imaging (MRI), ultrasonography, bone scintigraphy and positron 
emission tomography–computed tomography (PET-CT). A histological confirmation is fun-
damental for the therapy and should be conducted in all patients if possible. Bronchoscopy 
provides a sensitivity of 88% and 78% for central and peripheral tumors respectively (Rivera 
and Mehta 2007). An ultrasound or CT-guided lung biopsy, mediastinoscopy, endobronchial 
and esophageal ultrasonography with transbronchial needle aspiration (TBNA) of regional 
lymph nodes can also be performed (Hammerschmidt and Wirtz 2009). 
PET-CT is a widely used diagnostic modality which plays a crucial role in diagnosis, staging, 
restaging and therapy planning. Cancer cells have a better capability to uptake the tracer (most-
ly used is Fludeoxyglucose 18F) providing a precise demarcation of the primary tumor mass 
and allowing the detection of involved lymph nodes and distant metastasis. Because of the 
brain cells’ natural high glucose uptake activity, PET-CT is considered to be a low sensitive 
modality for diagnosing brain metastasis. Other limitations include false negative findings of 
small lesions or tumors with low metabolic activity as well as a high cost. Despite the PET-CT 
significance in the process of lung cancer diagnosis and treatment, it did not appear to improve 
the five-year survival of lung cancer patients (Chao and Zhang 2012). 
The evaluation of a patient’s functional performance is a part of the diagnostic process and is 
important to ensure the most appropriate therapy. This includes the evaluation of cardiovascu-
lar comorbidities, liver or renal impairment, and the assessment of functional operability 
(Hammerschmidt and Wirtz 2009). 
As with other solid tumors, lung cancer has been integrated to the Union for International 
Cancer Control (UICC) tumor, lymph node and metastasis (TNM) staging system since 1966. 
The first lung cancer TNM-staging review came to light in 1973 and was done by Mountain 
et al. The International Association for Study of Lung Cancer (IASLC) commenced a staging 
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project depending on a multi-centric, international database with a large pool of patients col-
lected over 12 years. The (IASLC) revision of lung cancer staging was published in the seventh 
edition of the “UICC- TNM classification of malignant tumors” in 2010. The new TNM clas-
sification is applicable for both NSCLC and SCLC (Mirsadraee et al. 2012). 
The TNM Staging system is considered to be most reliable prognostic factor in lung cancer 
recurrence and survival rate (Woodard et al. 2016). In the TNM staging system T stands for 
the size of the primary tumor in the long axis. In the 7th classification T1 and T2 tumors are 
further divided into subgroups. A major modification is the downgrading of other nodules 
found on the same lung lobe to T3 (was T4) and the consideration of other ipsilateral nodules 
outside the primary lobe, which are histologically similar to the primary tumor T4 instead of 
M1 (Carson and Finley 2011). 
N defines nodal involvement. Since the new data didn’t show a difference in nodal staging 
related survival, there were no changes made to nodal staging in the new 7th edition. There are 
many approaches to determine the level of nodal involvement. Studies show that the com-
bined use of endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) and 
esophageal endoscopic ultrasound needle aspiration (EUS-TBNA) has a higher sensitivity 
(93%) compared to mediastinoscopy (80-90%). Other techniques include computer tomogra-
phy (CT) and PET-CT with a sensitivity of 60% and 84% respectively. Anyway, the collection 
of the database used in the 7th classification preceded the prevalent use of PET-CT (Mirsadraee 
et al. 2012). 
M staging describes extranodal metastasis. In the majority of cases bronchial carcinomas are 
metastatic (stage IV) at time of diagnosis. Lung cancer is able to metastasize through blood 
and lymphatic vessels, ideally to the contralateral lung, liver, adrenal glands, bone and brain 
(Popper 2016). In the 7th edition of TNM staging, pleural or pericardial carcinosis is upgraded 
from T4 to a new category of M1a. To this category belongs contralateral lung metastasis. Ex-
trathorasic metastasis has been classified to M1b (Mirsadraee et al. 2012). 
In January 2017 the 8th  TNM stage classification of lung cancer was released and carried out 
some major changes. The  T1 and T2 tumor sizes were subdivided in 1 cm additions up to 5 
cm, where T3 was defined by tumors >5 but ≤7 cm, and T4 for tumors larger 7 cm or tumors 
involving the diaphragm. Tumors with extrathorasic metastasis were subdivided to M1b when 
it has one single metastasis and  M1c for tumors with multiple extrathoracic metastases 
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(Detterbeck 2018). A summary of the 8th TNM classification (Goldstraw et al. 2016; Detter-
beck 2018) is given in table 1 and table 2. 
Table 1: The 8th TNM clinical staging system for NSCLC 
T (primary tumor) 
0 No primary tumor 
Tis Carcinoma in situ  
T1 Tumor ≤3 cm 
T1mi Minimally invasive adenocarcinoma 
T1a Superficial spreading tumor in central airways∗∗ 
T1a Tumor ≤1 cm 
T1b Tumor >1 but ≤2 cm 
T1c Tumor >2 but ≤3 cm 
T2 Tumor >3 but ≤5 cm or involving visceral pleura or main bronchus  
T2a Tumor >3 but ≤4 cm 
T2b Tumor >4 but ≤5 cm 
T3 Tumor >5 but ≤7 cm or invading chest wall, pericardium, phrenic nerve; or separated 
tumor nodules in the same lobe 
T4 Tumor >7 cm or tumor invading: mediastinum, diaphragm, heart, great vessels, recur-
rent laryngeal nerve, carina, trachea, esophagus, spine; or tumor nodule(s) in different 
ipsilateral lobes 
N (regional lymph nodes) 
N0 No nodal metastasis 
N1 Metastasis in ipsilateral pulmonary or hilar nodes 
N2 Metastasis in ipsilateral mediastinal or subcarinal nodes 
N3 Metastasis in contralateral mediastinal, hilar, or supraclavicular nodes 
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M (distant metastasis) 
M0 No distant metastasis 
M1a Malignant pleural or pericardial effusion or pleural or pericardial nodules or sepa-
rate tumor nodule(s) in a contralateral lobe 
M1b Single extrathoracic metastasis 
M1c Multiple extrathoracic metastases in one or more than one organ 
∗Superficial spreading tumor of any size but confined to the tracheal or bronchial wall. 
Tumors causing atelectasis or bronchial obstruction are classified as T2a if >3 and ≤4 cm, 
T2b if >4 and ≤5 cm. 
(Goldstraw et al. 2016; Detterbeck 2018) 
 
 
Table 2: Overall NSCLC stages based on T, N and M criteria 
Stage Primary Tumor Lymphnode  Metastases 
0 Tis N0 M0 
IA1 T1a (mi) N0 M0 
 T1a N0 M0 
IA2 T1b N0 M0 
IA3 T1c N0 M0 
IB T2a N0 M0 
IIA T2b N0 M0 
IIB T1a-c N1 M0 
 T2a N1 M0 
 T2b N1 M0 
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Stage Primary Tumor Lymphnode  Metastases 
 T3 N0 M0 
IIIA T1a-c N2 M0 
 T2a-b N2 M0 
 T3 N1 M0 
 T4 N0 M0 
 T4 N1 M0 
IIIB T1a-b N3 M0 
 T2a-b N3 M0 
 T3 N2 M0 
 T4 N2 M0 
IIIC T3 N3 M0 
 T4 N3 M0 
IVA any T any N M1a 
 any T any N M1b 
IVB any T any N M1c 
(Goldstraw et al. 2016; Detterbeck 2018) 
1.1.5 Treatment 
The treatment choice depends mainly on the initial stage of the disease, as well as the patient’s 
functional performance and comorbidities. Accordingly, the first step is to determine the pur-
pose of the therapy, considering the patient’s life expectancy and quality. Decision-making 
through a multidisciplinary team results in better outcomes. 
About 25% of all cases present at early disease stages (stage I and II), where a curative therapy 
should be conducted. In operable patients, surgery, either lobectomy or pneumonectomy, is 
the treatment of choice. Most lung cancer patients are current or former smokers with concur-
rent pulmonary restrictions and cardiovascular comorbidities. Pulmonary function tests and 
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cardiovascular assessment are mandatory for all local therapy candidates. Patients may need to 
get cardiopulmonary function tests (Spiroergometry) or lung perfusion (Scintigraphy). Proce-
dures below lobectomy (wedge resection or segmentectomy) may be performed in primarily 
operable tumors in patients with functional restrictions. Studies show a high rate of recurrence 
and a decrease in the five-year survival in patients of sublober surgery when the tumor size 
exceeds 3 cm. The introduction of Video-assisted thoracoscopic surgery (VATS) provides a 
better post-operative course with fewer complications and minimizes the post-operative hospi-
tal stay period (van Schil et al. 2017; Gadgeel et al. 2012). 
Other curative treatment modalities for non-operable patients include conventional radiother-
apy (RT). Radiation pneumonitis is a major complication for this type of local therapy. Stereo-
tactic radiosurgery is an ingenious type of radiotherapy using a proton beam to deliver a high 
power of radiation to a small body area. This type of radiation shows high successful rates of 
local control with a five-year survival of more than 50%. The application of adjuvant chemo-
therapy in stage II and III in patients who have undergone curative surgery shows an increase 
of the five-year survival of about 5%. This should be considered in patients with a non-
complicated post-operative course with a good functional status. Typically four cycles of plati-
num-based dual chemotherapy are given. The aim of the adjuvant therapy is to reduce the re-
currence through undetectable micro metastasis (Gadgeel et al. 2012).  
As stated in the 8th UICC classification of lung cancer, stage III disease is subdivided into three 
groups: IIIA, IIIB and IIIC. Patients with T3N1M0 (Stage IIIA) disease undergo surgery with 
every effort to obtain disease-free margins (R0); in the case of a primary tumor mass more than 
5 cm or ipsilateral lymph node metastasis, an adjuvant chemotherapy should be conducted. In 
case of proven microscopic marginal residuals (R1), the choice of post-operative radiotherapy 
could be reviewed. N2 status disease is considered be a big controversy in thoracic oncology. 
Many clinical trials with different treatment modalities and different studies have failed to con-
clude the superiority of one single treatment modality in this case. Studies show a discrepancy 
in the disease free year survival, depending on the N2 status. Mediastinal nodal involvement 
(N2) with a concomitant ipsilateral node (N1) or a multi-stational N2 has proven to have a 
worse prognosis than a single nodal N2 disease. Treatment approaches vary between initial 
surgical treatment followed by adjuvant chemotherapy and starting with induction therapy 
followed by restaging and eventually surgical resection. All patients with suspected N2 status 
should undergo an invasive diagnosis (e.g. EBUS-TBNA) before surgical resection. The varia-
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tion of N2 status: single, multiple or bulky, and the assessment of collateral N1 status have 
implications on the treatment approach as well as free year survival rates (Gadgeel et al. 2012; 
Rocco et al. 2016; van Schil et al. 2017). The following table shows a subtyping of N staging 
criterion according to the 8th UICC classification: 
Table 3: Subdivisions of the N staging criterion according to the 8th TNM classification system 
Nodal subdivision Definition 
N1a Single N1 station 
N1b Multiple N1 stations 
N2a1 Single N2 station  
N2a2 Single N2 station (with N1 involvement) 
N2b Multiple N2 stations 
N3 Contralateral hilar or mediastinal lymph node stations or 
scalene or supraclavicular lymph nodes 
(van Schil et al. 2017) 
For (T4 with N0-1) stage III diseases, the size and the tumor invasion of the surrounding 
structure make a free marginal resection difficult to achieve. An induction therapy might be 
helpful before surgery (Gadgeel et al. 2012; Rocco et al. 2016; van Schil et al. 2017). 
More than 40% of NSCLC patients present with advanced disease at the time of diagnosis. For 
patients with advanced stages (stage IIIB and IV), studies have proven the superiority of sys-
temic therapy over best supportive care (BSC) in survival rates and life quality. In 2016, pem-
brolizumab was the first immune checkpoint inhibitor (ICI) to be approved as first-line mono-
therapy in advanced NSCLC. Pembrolizumab was approved as first-line treatment when at 
least 50% of tumor cells express PD-L1 in the absence of therapy-relevant mutations (Reck et 
al. 2019). Otherwise a combination of platinum-based (cisplatin or carboplatin) medications 
with third-generation cytotoxic agents are considered to be the choice of first-line treatment 
for advanced NSCLC. Patient performance (Eastern Cooperative Oncology Group, ECOG) 
scale 0–1 should be assessed before initiation of the therapy. In patients with reduced perfor-
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mance (ECOG 2) a monotherapy might be more sensible. Patients with poor performance 
(ECOG 3-4) should be offered the best supportive care (Bareschino et al. 2011; Zarogoulidis 
et al. 2013; Gadgeel et al. 2012). 
Table 4: Performance status according to the Eastern Cooperative Oncology Group  
Grade Performance status 
0 Active with no pre-disease performance limitations 
1 Limited hard physical activity with no restrictions in light 
activity 
2 Able to be self-caring, up and working for more than 50% 
of waking hours 
3 Limited self-care; sit or lie more than 50% of waking hours  
4 Disabled even in self-care  
5 Dead 
(Oken et al. 1982). 
The histological subgrouping of NSCLC has recently been playing a crucial role in therapy 
choice. Studies data shows a significant difference in the response of lung squamous cell carci-
noma (SCC) to cisplatin and gemcitabine versus cisplatin and pemetrexed. Non-squamous cell 
carcinomas also show a better response to cisplatin and pemetrexed than cisplatin and gem-
citabine, which might be due to an increased expression of thymidylate synthase , dihydrofolate 
reductase (DHFR) in SSC, which reduces the response to therapy with the third-generation 
cytotoxic antifolate agent pemetrexed. A combined therapy of a platinum-based agent and 
pemetrexed is considered the first-line therapy for non-squamous NSCLC (Bareschino et al. 
2011).The first-line therapy in advanced NSCLC is typically administrated for four cycles. In 
the case of an objective response or stable disease a maintenance therapy has appeared to delay 
the disease progress and increase the year survival (Gadgeel et al. 2012). 
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The detection of particular molecular properties in different carcinomas has brought the new 
generation of targeted therapy to light. This type of selective therapy depends on precise im-
munohistochemical features to interfere with the process of cell division, angiogenesis and 
apoptosis. The application of the targeted therapy in combination with the traditional chemo-
therapy as first-line treatment, as maintenance, or in second-line treatment, has been shown to 
improve the progression free time as well as overall year survival in patients with advanced 
NSCLC. The use of the novel monoclonal anti-angiogenic endothelial growth factor (VEGF) 
antibody bevacizumab in combination with a platinum-based agent and pemetrexed in permit-
ted patients of non-squamous NSCLC prolongs the time to progression and improves the ob-
jective response (OR) (Reck and Rabe 2017; Mayekar and Bivona 2017; Assoun et al. 2017). 
Examples of commonly used targeted therapy agents are listed in the following table (Reck and 
Rabe 2017): 
Table 5: Examples of  targeted therapies used in the treatment of NSCLC 
Drug  Target Indication  
Erlotinib  EGFR  EGFR-mutated metastatic 
NSCLC 
 
Osimertinib EGFR, T790M mutation EGFR-mutated NSCLC with 
T790M mutation  
Crizotinib ALK, ROS1 ALK-positive or ROS1-
positive metastatic NSCLC  
Bevacizumab VEGF Advanced non-squamous 
NSCLC combined with plati-
num-based chemotherapy as 
first-line therapy. 
ALK: anaplastic lymphoma kinase; EGFR epidermal growth factor receptor; VEGF: vascular 
endothelial growth factor, ROS: proto-oncogene 1, receptor tyrosine kinase.
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1.2 Cancer Immunotherapy 
1.2.1 Cancer Immunity and Immunoediting 
The relationship between our immune system and cancer has been always a point of interest. 
Several preclinical and clinical observations revealed the crucial role of the immune system in 
cancer development. Earlier, preclinical studies compared the development of cancer in im-
munocompetent and immunocompromised mice. Other studies focused on cancer incidence 
in patients with congenital or acquired immunodeficiencies and the increased risk of cancer in 
elderly people (Finn 2018). 
The fact that cancer cells release specific antigens is pivotal in understanding cancer immunity 
(Rosenberg 2004). Neo-antigens resulting from mutant cancer cells are responsible for stimu-
lating clinical immune response (Farkona et al. 2016). If an alteration in cell function or struc-
ture occurs, the immune system is going to raise alarms using different mechanisms. These 
include: cytokines, cells lysis products, expression of stress ligands and, eventually, tumor-
specific antigens (Schreiber et al. 2011). The concept of cancer immunotherapy is to support 
our own immune system to recognize cancer antigens and to trigger an appropriate immune 
response (Marin-Acevedo et al. 2018). Immunosurveillance is the process by which cells of 
adaptive immunity recognize neoplastic transformed cells and eliminate them. Immunosurveil-
lance is crucial in immune system-cancer interaction and is the first step in immunoediting 
(Teng et al. 2013).  
Immunoediting describes the immune system behavior toward cancer cells. Immunoediting is 
a process of three phases: Elimination, Equilibrium and Escape. Antigen-presenting cells (APC) 
cells are responsible for detecting and presenting cancer-specific antigens. Elimination begins 
in the pre-clinical phase. This means before the tumor becomes visible. When intrinsic tumor 
suppressors like P53 fail to prevent cells from malignant transformation, transformed cells 
produce stress ligands and antigens expressed by the major histocompatibility complex class I 
molecules (MHC 1) or the transmembrane receptor Natural killer group 2 member D 
(NKG2D), which will be recognized by cells of both innate and adoptive immunity like Natu-
ral killers (NK) and cluster of differentiation 8 (CD8) T cells. This will eventually initiate se-
quential reactions of tumor-antigens presentation by dendritic cells (DCs) at most, release 
gamma interferon (IFN-γ) and cytokines which recruit more immune cells to the tumor’s mi-
croenvironment. IFN-γ has anti-proliferative anti-angiogenic activities against cancer cells and 
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activates macrophages to produce reactive oxygen species (ROS). NK and CD8 T cells induce 
apoptosis through activation of the so-called ‘death receptors’ Fas (CD95/APO-1) and tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL) on cancer cells. DCs migrate to the 
tumor-draining lymph nodes (TDLNs) and activate CD4 T helper cells, which maintain the 
production of tumor-specific CD8 T cells and increase their activity by producing Interleukin 2 
(IL-2). These apoptotic tumoricidal activities will eliminate the transformed cancer cells. A 
complete tumor eradication means the end of immunoediting (Dunn et al. 2004; Germenis and 
Karanikas 2007; Schreiber et al. 2011; Mittal et al. 2014). 
Immune self-limitation through negative feedback inhibitors at the site of the inflammation 
works to restrain the anti-tumor immune activity. APCs release of inhibitory cytokines like 
Interleukin 10 (IL-10) and transforming growth factor-β (TGF-β) may bring the tumor cells to 
a state of dormancy (Kim et al. 2007). 
The state of dormancy or Equilibrium describes the phase by which the cells of adaptive im-
munity are not able to eradicate tumor cells completely but contain them. This state of latency 
could explain the long period between cancer cells’ transformation and the time of clinical 
disease recognition. It can also explain cancer recurrence either locally or as metastatic disease. 
Pre-clinical modules suggest that (IFN-γ) released by tumor antigen-specific T cells play a role 
in inhibiting disseminate micrometastasis (Vesely et al. 2011). In time, sustained sculpting of 
cancer cells results in eliminating immunogenic cancer cells, which consequently results in the 
selection of low immunogenic cancer cells. This indirect selection of low immunogenic cancer 
cells is the core of immunoediting (Kim et al. 2007). 
Cancer Escape represents the failure of the immune system to maintain the state of equilibrium. 
Tumor cells go through genetic and epigenetic changes and overcome the state of balance in 
favor of cancer outgrowth. The immune system contributes to this by immunselections of 
resistant cancer variants and by the inhibition of the tumoricidal immune activity (Vesely et al. 
2011). Tumor cells are mainly responsible for escape by reducing their own exposure to the 
immune system through reduction in tumor recognition by presenting low immunogenic anti-
gens or by alternating gene presentation of MHC class I and its co-molecules or increasing the 
production of anti-apoptotic molecules like Bcl2. In addition tumor cells express immunosup-
pressors like VEGF, PD-1 and PD-L1 at the tumor-immune cells’ interaction surface (Mittal et 
al. 2014). 
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1.2.2 Classes of cancer immunotherapy 
The introduction of interferons (IFN-α,-β,-γ) in treating some types of malignancies like 
chronic myeloid leukemia (CML) and non-Hodgkin lymphoma (NHL) represents the first gen-
eration of immunotherapy. Interferons are glycoproteins with a dose-dependent immunomod-
ulatory effect (Murphy 2010; Stanculeanu et al. 2016). Interferon has an antitumor immune 
stimulatory effect through activation of natural killers, increasing cancer antigen presentation 
by increasing MHC expression and provoking the differentiation of Th1 cells. On the other 
hand, interferons offer immunosuppressing effects by stimulating IL-10 production and en-
hancing the adaptive immunity to T-cells by up-regulating PD- L1 on APCs and tumor cells. 
This dual functionality maintains the homeostatic role of interferons during an extensive in-
flammatory state as a self-protection mechanism (Minn 2015). 
Cancer vaccine is an approach that mainly increases immune system recognition of cancer cells 
by exploiting high immunogenic tumor-associated antigens (TAAs) and increasing their 
presentation. Peptide-based vaccines utilize the tumor-associated antigens’ epitopes presented on 
MHC in the tumor microenvironment to escalate CD8 T cells’ activity against these antigen-
carrying cells. They can be administrated with cytokines like granulocyte macrophages’ colonies 
stimulating factor (GM-CSF) to increase their exposure on DCs. These epitopes are peptides 
of short amino acid chains that are cost effective and simple to produce. However, obtaining 
immunogenic epitopes is challenging and restricted to their expression on MHC. APCs-based 
vaccine is a safe therapy which is proven to induce a significant tumor regression. Patients’ 
APCs, mainly the most effective DCs, could be extracted and cultured in vitro with TAAs and 
APCs stimulating factors and then retransferred to patients with the aim of inducing CD8-
specific cancer cells. A landmark in APCs-based vaccine is the FDA-approved autologous sip-
uleucel-T for hormone refractory prostate cancer. Cancer cells-based vaccine is another type of 
cancer vaccine based on delivering autologous or allogeneic cancer cells to possibly expose the 
immune system to numerous MHC nondependent antigens. M-Vax is an autologous tumor 
cells-based vaccine which showed clinical efficacy treating metastasized melanoma. Oncolytic 
viruses or virus-based vaccine is one of the first-used cancer vaccines. They are used like con-
ventional vaccines in term of cancer prevention. For example, HBV vaccine reduced the inci-
dence of hepatocellular carcinoma and the Human papilloma virus (HPV) vaccine against cer-
vical carcinoma (Butterfield 2015; Raval et al. 2014; Ventola 2017). 
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Monoclonal antibodies (mAbs) are a novel class of cancer immunotherapy that has been proving its 
clinical efficacy. The development of new biotechnological techniques like hybridoma technol-
ogy revolutionized this type of immunotherapy. Monoclonal antibodies’ production requires a 
precise understanding of cancer biology, the distribution of the targeted antigens in malignant 
and in normal cells, and the role that these targeted antigens play in cellular proliferation and 
programmed cell death (Scott et al. 2012). 
Monoclonal antibodies have different immunomodulatory pathways (Adams and Weiner 2005; 
Simpson and Caballero 2014): 
1- Antibody-dependent cytotoxicity: When an antibody binds to an antigen on a target cell 
and the fragment crystallizable (Fc) of the antibody engages the Fc gamma receptor (FcgR) 
on the effector cells, which are, in this case, natural killers and macrophages. This leads to 
cell destruction and increases tumor debris exposure to APCs. Consequently, this will trig-
ger production of tumor-specific cytotoxic lymphocytes (CTLs). This pathway is FcgR-
dependent. Some preclinical data supports the importance of this pathway. For example, 
an inferior antitumor activity of the monoclonal antibodies (rituximab) on FcgR-deficient 
mice compared to wild mice. There is little clinical data on this type of immunomodula-
tion. 
2- Complement-mediated cytotoxicity (CDC): The antibody antigen complex is able to initi-
ate the naturally occurring complements-dependent cytotoxicity. The most effective anti-
bodies to stimulate the complements pathway are IgM. However, their lack of the extrava-
sation capability makes the IgG subclasses more frequently used in clinical practice. CDC 
is one of the rituximab mechanisms of action. 
3- Antibody-tumoricidal conjugate: the concept of this approach is to deliver cytotoxic agents 
or radioisotopes to targeted tumor cells through tumor-specific antibodies with the aim to 
reduce systemic toxicity. The FDA-approved Anti-CD30 antibody-drug conjugate (bren-
tuximab vedotin-monomethyl auristatin E) is a successful example used in treating CD30-
expressing lymphomas (Yi et al. 2017). 
1.2.3 Checkpoint pathway inhibitors 
To understand the pivotal role of the checkpoint pathways in cancer immunity we summarize 
the cancer immune cycle as follows: cancer-specific antigens will be presented on the MHC I 
of the APCs or MHC II of the T regulatory cells respectively. This will activate cytotoxic T 
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cells (CD8) which in turn migrate to the tumor site and initiate an antitumor reaction (Dine et 
al. 2017). The interaction between cytotoxic T cells and APCs or cancer cells depends mainly 
on the T cell receptor (TCR) which binds to antigen peptides on the effector cells (APC, can-
cer cells) as a first signal. However, a second signal between a group of transmembrane pro-
teins expressed on the T cells membrane, and their ligands on the effector cells, is necessary to 
complete priming of native T cells. These transmembrane proteins belong to a superfamily of 
immunoglobulin that regulates T cells’ activity. The first-known co-stimulatory receptor ex-
pressed on native T cells is the CD28 receptor. When it binds to its ligands (B7-1 and B7-2) on 
the APC, intracellular pathways will be activated to produce cytokines such as IL-2 which 
promote further T cell activity. Checkpoint receptors also belong to this superfamily of trans-
membrane proteins and are responsible for the inhibitory signaling which will eventually down 
regulate TCRs and T cells’ anticancer activity. Inhibitory checkpoint receptors like CTLA-4 
(Cytotoxic T Lymphocyte Antigen-4), PD-1 (Programmed Death-1), LAG-3 (Lymphocyte 
Activation Gene-3), TIM-3 (T cell Immunoglobulin and Mucin protein-3) act in the context of 
an immune system self-protection mechanism to avoid an overt immunoreaction and to regu-
late its response toward self-proteins (Nirschl and Drake 2013). 
The longstanding exposure of cytotoxic T cells (CTL) to specific antigens during chronic viral 
infections or persistent tumor antigen stimulation could result in T cells’ shut down. This phe-
nomenon is called ‘T cell exhaustion’ and it describes a gradable loss of cytotoxic T cell func-
tions including: the ability to secrete cytokines, the capacity of proliferation and cytotoxicity, as 
well as degranulation and memory cells’ generation. This state of T cells dysfunction is con-
nected to up-regulation of the checkpoint co-inhibitory receptors on lymphocytes of peripheral 
blood obtained from cancer patients or patients with chronic viral infections like HIV, and 
Hepatitis B and C. T cell exhaustion depends on the duration and degree of T cells’ exposure 
to an antigen. Preclinical studies show an increase of exhausted T cells in the tumor microenvi-
ronment compared to those in peripheral blood. PD-1 up-regulation in the tumor microenvi-
ronment is considered to be a hallmark of CTL exhaustion (Okoye et al. 2017; Granier et al. 
2017). 
Cytotoxic T Lymphocyte Antigen-4, also called (CD152), is a co-inhibitory homolog of the 
transmembrane co-stimulatory protein CD28 with a higher binding affinity to their mutual 
ligands B7-1 and B7-2 presented on APCs. CTLA-4 is a central T cells’ regulator, it acts pri-
marily on nodal T cells, comparing with the programmed cell death PD1 checkpoint receptor 
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which appears to be predominant in peripheral T lymphocytes (Buchbinder and Desai 2016). 
Mutations in the CTLA-4 coding gene may lead to loss of its down regulatory function and 
may be seen in insulin-dependent diabetes mellitus and many other autoimmune disorders like 
systemic lupus erythematosus (SLE) (Fagerberg et al. 2014). CTLA-4 is an intracellular glyco-
protein that exists almost only in T lymphocytes. T cell second signal activation through 
CD28:B7-1 and B7-2 conjugation is an activation signal for CTLA-4. After CTLA-4 activation 
it will be translocated to the immune synapse to complete CD28 in binding to the B7 ligands, 
which in turn down regulate T cell activity through an intracellular cascade that leads to inhibi-
tion of TCR and decreases cytokines secretion (Intlekofer and Thompson 2013). CTLA-4 is 
also involved in the modulation of the T regulator cells (Tregs) (Callahan et al. 2010; Buch-
binder and Desai 2016). 
 
Figure 2: The mechanism of CTLA-4 pathway inhibition: The CTLA4 antibody interferes with the 
down-regulatory effect of the peripheral membrane protein (B7) by blocking its binding site at the 
CTLA4 checkpoint receptor. APC: antigen presenting cell, CTLA: cytotoxic T lymphocyte antigen-4,  
HLA: human leukocyte antigen, TCR: T cell receptor 
Ipilimumab is a CTLA-4 inhibitor. A recombinant human immunoglobulin (Ig) G1 monoclo-
nal antibody binds to the CTLA-4 receptor and detains its inhibitory action. Ipilimumab is an 
approved anti-cancer monoclonal antibody and it is a successful treatment for metastatic mela-
noma (Della Vittoria Scarpati et al. 2014). 
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Programmed cell death 1 (PD 1 or CD279) is also a transmembrane checkpoint protein of the 
globulin superfamily with a well-defined function in immune down regulation. It is a 288 ami-
no acid with an extracellular domain and cytoplasmic tail (Dong et al. 2016). It was thought to 
be an apoptosis-regulator protein; it was tested in PD1-deficient mice and recognized in 1999 
as a cell-mediated immunity down-regulator by Tasuku Honjo and colleagues at Kyoto Univer-
sity. In preclinical studies PD 1 deficiency elicited a spontaneous autoimmune disease pattern. 
PD 1 is expressed on CD4 and CD8-activated cells, APCs (DC and monocytes) as well as T 
regulatory cells (Bardhan et al. 2016). PD 1 is highly expressed on the T cells in a tumor micro-
environment due to chronic antigen exposure, and its expression is considered a sign of T 
cells’ exhaustion (Dong et al. 2016). PD 1 expression is also up-regulated through γ -chain cy-
tokines such as IL-2, IL-7, IL-15, and IL-21 (Bardhan et al. 2016). PD 1 engagement with its 
ligand PD-L1 (B7-H1) and PD-L2 (B7-DC) triggers termination of T cells’ activity. PD-L1 is 
expressed by cancer cells and APCs, and has a higher affinity to PD -L1 than PD-L2 (Alsaab et 
al. 2017). The PD 1 PD-L1 engagement on antigen-presenting cells hinders specific T cell acti-
vation and encourages the differentiation of Treg. This engagement in the tumor microenvi-
ronment through the PD-L1 expressed on tumor cells inhibits T cells’ antitumor activity. The 
PD 1 pathway activation causes alteration in the intracellular pathways to decrease T cell cyto-





Cancer Immunotherapy 20 
               
Figure 3: The mechanism of PD1/PD-L1 pathway inhibition: The PD1 or PD-L1 antibodies bind to 
either the PD1 checkpoint receptor or to PD1 ligand to interfere with the down-regulatory effect of the 
PD/PD-L1 pathway on T-cell activity. HLA: human leukocyte antigen, PDL: programmed cell death 
ligand, PD: programmed cell death receptor, TCR: T cell receptor. 
 
The introduction of PD-1/PDL-1 inhibitors is a big step forward in treating different ad-
vanced malignancies. Several clinical trials have demonstrated the efficacy of programmed cell 
death inhibitors and resulted in the approval of many new anti-cancer medications (Sunshine 
and Taube 2015). 
Pembrolizumab (KEYTRUDA®; Merck) is a highly selective humanized IgG4 monoclonal 
PD 1 receptor inhibitor approved as a first-line therapy for metastatic NSCLC with a PD-L1 
tumor proportion score (TPS) ≥ 50% in the absence of ALK and EGFR mutations (Lim et al. 
2016), as well as a second-line therapy for patients with a TPS ≥ 1% who failed to respond to 
conventional platinum-based chemotherapy (Rihawi et al. 2017) pembrolizumab therapy shows 
efficacy treating PD-L1 positive malignancies such as NSCLC, head and neck cancer, gastric 
carcinoma and urothelial cancer as well as hematological malignancies like PD-L1-positive 





The main aim of this work is to validate a weighted score of various laboratory values in a 
population of patients with metastatic NSCLC treated in the first line with pembrolizumab. 
The mentioned score has been described earlier in a pretreated population of patients with 
advanced NSCLC who received treatment with nivolumab. As it was possible that the score 
had to be slightly adapted in first-line treatment, other clinical, radiological and pathological 
characteristics were registered as well and correlated with patient response to treatment with 
pembrolizumab. As there is no indisputable test to predict patient response to treatment with 
immune-checkpoint-inhibitors (ICI), a score could be a helpful tool in monitoring patients 
under treatment with ICI, especially as during treatment with ICI a so-called pseudoprogres-
sion is hard to distinguish from a really progressive disease. 
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2 Material and methods 
2.1 Overview 
We retrospectively analyzed 66 consecutive patients who received therapy with pembroli-
zumab at the LKI Lungenfachklinik Immenhausen (Medical director Prof. Dr. med. S. Andre-
as) who commenced treatment between 16th of November 2016 to 30th of April 2018. Pem-
brolizumab is approved in Germany as a first-line monotherapy in patients with metastatic 
non-small cell lung cancer with PD-L1-expressing tumors (Tumor Proportion Score [TPS] ≥ 
50%) without targetable EGFR or ALK driver-mutations. 
All patients were treated with pembrolizumab at a flat dose of 200 mg as an intravenous infu-
sion over one hour every three weeks, equivalent to one cycle. The majority of patients re-
ceived their therapy in the oncological outpatient clinic. Patients with poor clinical status were 
admitted to an inpatient ward if necessary. On each day of the treatment, after taking a brief 
clinical history and a clinical examination, patients received a chest X-ray, and blood tests of 
full blood count, liver, kidney functions tests and C-reactive protein. Side effects and weight 
were documented on every visit. The therapy was continued for up to six cycles if no intolera-
ble adverse events occurred. After each three cycles, a chest CT was performed and evaluated 
according to RECIST 1.1. 
 
2.2 Documentation 
The documentation of patients’ data was carried out with the spreadsheet program Microsoft® 
Excel 2016, Redmond. For a retrospective data collection we utilized patients’ information and 
laboratory parameters from the patient information software Medico ® Idstein and medical 
records at the LKI Lungenfachklinik Immenhausen. This includes discharge or transfer reports 
and documents of a local tumor board. The data were anonymized by giving each patient an 
identification number. The collected data are summarized in (Table 6). 
  
Material and Methods 23 
Table 6: Overview of the extracted data form patients’ medical records 
Extracted data Clinical variables, range and measur-
ing units 
Date of birth  Age in years 
Gender Male/female 
Smoking status  Current, former or never smoker 
Smoking quantity  Pack years 
Tumor main histological type  Adenocarcinoma (ADC), squamous cell car-
cinoma (SCC), adenosquamous carcinoma 
(ASC), sarcomatoid carcinoma or not other-
wise specified (NOS) 
KRAS, MET and TP53 Mutation Positive: mutated 
Negative: wild-type 
PD-L1 Status  TPS score, range: 0.5-1.0 
IC score, range 0.0-1.0 
Date of first diagnosis Survival time in days 
Date of death (if available) 
Date of last contact with the patient  
GL-Index  103 µl/ 103 µl 
LDH  U/L 
CRP  mg/L 
Weight  Kg 
Target lesion size in millimeter at 1st day of the thera-
py and after every 3 cycles. Target lymph nodes’ and 
secondary lesions’ size in millimeters at 1st day of the 
therapy and after every 3 cycles. 
To define the treatment response according 
to revised RECIST1.1 criteria (table 7) 
Pack years: (number of packs of cigarettes smoked per day x the number of years the person has 
smoked), KRAS: Kirsten rat sarcoma virus, MET: mesenchymal-epithelial transition factor p53: tumor 
suppressor. TPS: tumor proportion score, IC: PD-L1 infiltration in immune cells. GL-Index: granulo-
cytes (neutrophils)/lymphocytes [103 x microliter/ 103 x microliter]. LDH: lactate dehydrogenase 
units/liter. CRP: c reactive protein milligram/liter. Kg: kilogram.  
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2.3 Laboratory diagnostics and weight 
In our analysis, we studied biomarkers that might have a potential prognostic value in patients 
with NSCLC. We included measures of lactate dehydrogenase (LDH) (Petrelli et al. 2015), c-
reactive protein (CRP) (Koch et al. 2009) and the granulocyte to lymphocyte index (Gu et al. 
2015) at baseline and at every therapy cycle. The longitudinal changes in the laboratory param-
eters were calculated at days 43 and 106 of the treatment and correlated to changes in tumor 
size obtained from CT- imaging. Likewise, the longitudinal changes in body weight were corre-
lated to treatment response as well. Further, values of laboratory parameters and weight were 
integrated to a score that was proposed to predict treatment response to ICIs.    
2.4 Histopathological Examination 
The histological and molecular pathological examinations were carried out for the main tumor 
histology and possible mutations in the KRAS protein (Kirsten rat sarcoma virus), mesenchy-
mal-epithelial transition factor (MET) and tumor suppressor p53. PD-L1 expression was eval-
uated in diagnostic biopsies using an immunohistochemical staining with PD-L1 antibodies 
22C3 pharmDx (Dako, Inc.). PD-L1 status was expressed as a percentage of PD-L1 positive 
tumor cells by a tumor proportion score (PD-L1 TPS), as well as the PD-L1 expression in 
immune cells (PD-L1 I.C). These features were inserted into our data and stratified in each of 
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2.5 Evaluation of patients’ response according to the RECIST 1.1 
As already stated, a restaging computer tomography study of the chest was done after every 
three cycles of the therapy. The new results including the size of the primary lesion, secondary 
lesions or lymph nodes and newly detected lesions were measured, evaluated and compared to 
the baseline chest CT at day one of the therapy. After ruling out patients with early death (who 
died before the first CT-scan) the rest of the patients were classified to: stable disease (SD), 
real progressive disease (RPD) and objective response (OR). The restaging was repeated after 
six cycles when a pseudo-progressive disease (PsPr) was added to the response groups. The 
evaluation was done in the Lungenfachklinik Immenhausen based on new response evaluation 
criteria in solid tumors, revised RECIST 1.1 guidelines (Eisenhauer et al. 2009), summarized in 
table 7. 
Table 7: Treatment response according to revised RECIST 1.1 criteria 
Response group  Definition  
Complete response  Disappearance of all target lesions and re-
duction of pathological lymph node diameter 
for < 10 mm in the short axis.  
Partial response  
 
 
Persistence of target lesions of >30% reduc-
tion in the sum of the longest diameter.  
Progressive disease  Increase of the sum of the largest diameter 
of target lesions by >20% compared with 
the longest sum diameter before treatment 
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2.6 Statistical Analysis 
For each response group, patients’ features and clinical variables were presented by mean±sd 
(continuously scaled) or by absolute and relative frequencies (nominally scaled). Each clinical 
variable was tested and compared in all response groups by an appropriate test, ex.: the 
ANOVA analysis and the Fisher's exact test (Du Prel et al. 2010). The change from baseline 
value (Delta) for each potential variable (weight, LDH, CRP, GL-Index and the tumor size) 
was calculated at predetermined points of time (day 43 and 106) to correlate the values with 
tumor response according to CT scans. The development over time was visualized using medi-
an boxplots overlaid with line plots. 
In order to obtain a prediction score that works robustly independent of the actual day, values 
of potential variables from six points time (days: 1- baseline, 22, 43, 64, 85, and 106 of the 
treatment) were included in data testing. Additionally, gender, age, histological type, PD-L1 
TPS, PD-L1 I.C, and smoking status were part of the potential predictors. 
The tested predictor is composed of a two-stage hierarchically structured receiver operating 
characteristic (ROC) analysis (Hajian-Tilaki 2013) for each variable of the tested data. In its 
first stage, the response group RPD was separated from the other response groups. In its sec-
ond stage, the response group OR was separated from the remaining groups SD and PsPr. In 
both ROC analyses a cutoff corresponding to the Youden index was used. For each variable, 
samples classified as RPD get zero points, samples classified as SD or PsPr get 1 point, and 
samples classified as OR get 2 points in the predictor. The sum of these points constitutes the 
overall prediction score. 
The classification performance has been evaluated in a 10-times repeated 10-fold cross valida-
tion (CV) (Simon et al. 2011) . The scores of the patients in the test set have been calculated at 
day 43. The difference of the assigned scores between the groups has been assessed using a 
linear mixed effect model including the results across all 10 repeats of the CV. 
A classification into RPD vs. the other response groups (non-RPD) was achieved via a cutoff 
on this score. The cutoff was chosen at the Youden index in the ROC analysis. 
The performance of this predictor was assessed by means of a 10-times repeated stratified 10-
fold cross validation. The evaluation was performed using data from the baseline and day 43. 
The accuracy, area under the curve (AUC), and the achieved sensitivity at a specificity of 50 % 
at best setting were reported. 
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The overall survival was analyzed via two separate Cox regressions (Stel et al. 2011) , the first 
to assess the effect of all response groups on the survival time and the second to assess the 
effect of the derived predicted scores at day 43 on survival. Kaplan-Meier curves have been 
created to display these effects.  
The significance level was set to alpha = 50% for all statistical tests. The statistical analysis was 
carried out by Dr. Andreas Leha (Head of central service unit - Department of Medical Statis-
tics at University medical center, Gottingen). All analyses were performed with the statistics 
software R (version 3.5.1; R Core Team 2018). 
 
2.7 Ethics 
This study was approved by the Ethics Committee of the University Medical Center, Göttin-
gen (application number 11/4/18). The principles of data protection complied with the law of 




3.1 Patients’ main characteristics 
Patients’ characteristics were analyzed at the baseline for the whole population and then for 
each of the five response groups. 
Table 8: Baseline demographic and clinical characteristics  
Parameter Level Value 
Total number  66 
Gender   
 Female 24 (36.4%) 
 Male 42 (63.6%) 
Age in years   
 mean ± sd 70 ± 9.2 
 median (min; max) 71 (50; 87) 
Smoking status   
 Current smoker 33 (50.0%) 
 Former smoker  27 (40.9%) 
 Never smoker 5 (7.6%) 
 Passive smoker 1 (1.5%) 
Smoking quantity  
(pack years) 
  
 mean ± sd 42 ± 29 
 median (min; max) 40 (0; 140) 
 Missing 3 
Results 29 
About 63% of the patients were males. The median age at time of diagnosis was 71 years and 
the youngest patient was diagnosed at the age of 50. About 91 % of the patients have had a 
known tobacco consumption with a median quantity of 40 pack years. One patient was a pas-
sive smoker and the rest 7.6% (n=5) were never smokers. 
According to patient response the patient population (n=66) was further divided into the fol-
lowing response groups based on the RECIST 1.1 on days 43 and 106: 
Table 9: Classification of patients according to objective response rate 
Objective response rate (ORR) Number of patients 
ED 9 (13.85%) 
OR 27 (41.54%) 
PsPr 6 (9.23%) 
RPD 14 (21.53%) 
SD 9 (13.85%) 
NA 1 
ED: early death, OR: objective response, PsPr: pseudoprogression, RPD: real progressive dis-
ease, SD: stable disease, NA: not available. 
Patients with early death (n=9) are those who died before completing the first three cycles of 
the treatment, i.e., in the first 43 days and didn’t receive a follow-up chest CT. ‘’Not Available’’ 
represents one patient who had his therapy with pembrolizumab ended after one cycle due to 
suspected pembrolizumab-induced pneumonitis. Diagnosing patients with pseudoprogression 
was carried out at the second follow up after day 106. 
 In order to study each group separately, we analyzed the baseline clinical characteristics for 
each group separately as presented in table 10:
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Table 10: Baseline demographics and clinical characteristics according to response group 
Parameter Level ED OR PsPr RPD SD P-value Test 
n  9 27 6 14 9   
Gender       0.13 Fisher's Exact Test 
for Count Data 






















Age in years       0.46 Analysis of Variance 
 mean ± sd 72 ± 7.1 69 ± 7.8 68 ± 9.1 74 ± 12 72 ± 8   
 median   
(min; max) 
71   
(60; 82) 
69    
(55; 87) 







Smoking status       0.70 Fisher's Exact Test 














 Former smoker 5 10 2 7 3   
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Parameter Level ED OR PsPr RPD SD P-value Test 




























ty (pack years) 
      0.24 Kruskal-Wallis rank 
sum test 
 mean ± sd 33 ± 23 44 ± 29 45 ± 17 37 ± 38 54 ± 28   
 median 
(min; max) 
35    
(0; 80) 
40    
(0; 120) 
50    
(20; 60) 
30    
(0; 140) 
48   
(30;12) 
  
 missing 0 1 0 1 1   
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Almost two-thirds of the patients responded well to pembrolizumab treatment. About 35% 
had a progressive disease or died early. The table shows variations in patients’ baseline features 
in all response groups. The medians of age for objective response and real progressive disease 
were 69 and 80 respectively. About 86% of patients with progressive disease were males and 
only one female patient had a PsPr (n=6). There were five never smokers, one died early, two 
had OR and the other two patients had RPD. 
3.2 Pathological characteristics 
In addition to the pathological subtypes of the tumor, patients were tested for programmed cell 
death ligand (PD-L1) expression in tumor cells represented by Tumor Proportion Score (TPS) 
as well as for PD-L1 infiltration in immune cells at the tumor site (I.C.). Moreover, patients with 
non-squamous cell cancer (n=46) were investigated for mutations in the oncogenes: Kirsten Rat 
Sarcoma virus (KRAS), tyrosine-protein kinase (Met) and Tumor Protein 53 (TP53). 
Table 11: Baseline tumor histology, molecular pathology and immunohistochemistry 
Parameter Level Value 
N  66 
Histology    
 ADC 43 (65.2%) 
 NOS 1 (1.5%) 
 SCC 20 (30.3%) 
 Sarcomatoid carcinoma  1 (1.5%) 
 ASC 1 (1.5%) 
PD-L1 TPS   
 mean ± sd 0.78 ± 0.17 
 median (min; max) 0.8 (0.5; 1) 
PD-L1 I.c   
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Parameter Level Value 
 mean ± sd 0.21 ± 0.26 
 median (min; max) 0.1 (0; 0.9) 
 missing 4 
KRAS mutation   
 neg. 27 (57.4%) 
 pos. 20 (42.6%) 
 missing 19 
MET mutation   
 neg. 41 (87.2%) 
 pos. 6 (12.8%) 
 missing 19 
TP53 mutation   
 neg. 28 (59.6%) 
 pos. 19 (40.4%) 
 missing 19 
neg.: means wild type non-mutated gene. pos.: mutated genes. The 19 missing come from patients with SCC 
who were not tested for mutations. ADC: adenocarcinoma. NOS: not otherwise specified. SCC: squamous 
cell carcinoma. ASC: adenosquamous carcinoma. sd.: standard deviation, PD: programmed cell death, TPS: 
tumor proportion score, I.c.: immune cells, KRAS: Kirsten rat sarcoma, MET: mesenchymal-epithelial tran-
sition factor p53: tumor suppressor. 
The majority of patients had adenocarcinoma (65%) followed by squamous cell carcinoma 
(30%). As the least accepted TPS was 50%, we had a TPS median of 80%. The PD-L1 I.c is 
not one of the prerequisites to initiate a monotherapy with pembrolizumab and shows a wide 
variation (0-90%). KRAS mutation was prevailing (42.6%) followed by TP53 mutation in 40% 
of the tested patients. 
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Table 12: Baseline tumor histology, molecular pathology and immunohistochemistry according to response group 
Parameter Level ED OR PsPr RPD SD P- 
value 
Test 
n  9 27 6 14 9   




 ADC 8 (88.9%) 18 (66.7%) 4 (66.7%) 7 (50.0%) 5 (55.6%)   
 NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (7.1%) 0 (0.0%)   
 PEC 1 (11.1%) 7 (25.9%) 2 (33.3%) 6 (42.9%) 4 (44.4%)   
 Sarcomatoid 0 (0.0%) 1 (3.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%)   
 SqAD 0 (0.0%) 1 (3.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%)   
PD-L1 
TPS 
      0.60 Analysis of 
Variance 















Parameter Level ED OR PsPr RPD SD P- 
value 
Test 
PD-L1 I.c       0.53 Analysis of 
Variance 














 missing 0 1 0 2 1   
KRAS 
mutation 




 neg. 5 (62.5%) 10 (50.0%) 4 (100.0%) 6 (66.7%) 2 (40.0%)   
 pos. 3 (37.5%) 10 (50.0%) 0 
(0.0%) 
3 (33.3%) 3 (60.0%)   
 missing 1 7 2 5 4   
 
 














 neg. 6 (75.0%) 18 (90.0%) 4 (100.0%) 7 (77.8%) 5 (100.0%)   
 pos. 2 (25.0%) 2 (10.0%) 0 (0.0%) 2 (22.2%) 0 (0.0%)   
 missing 1 7 2 5 4   
TP53 
mutation 




 neg. 3 (37.5%) 12 (60.0%) 3 (75.0%) 5 (55.6%) 4 (80.0%)   
 pos. 5 (62.5%) 8 (40.0%) 1 (25.0%) 4 (44.4%) 1 (20.0%)   
 missing 1 7 2 5 4   
neg.: means wild type non-mutated gene. pos.: mutated genes. The 19 missing come from patients with SCC who were not tested for mutations. ADC: adenocarci-
noma. NOS: not otherwise specified. SCC: squamous cell carcinoma. ASC: adenosquamous carcinoma. sd.: standard deviation, PD: programmed cell death, TPS: 
tumor proportion score, I.c.: immune cells, KRAS: Kirsten rat sarcoma, MET: mesenchymal-epithelial transition factor p53: tumor suppressor.
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Table 12 shows the histological features in all response groups. About 34% of patients with 
SSC (n=20) had ED or RPD. The numbers are similar in patients with ADC (n=42), 35% had 
ED or RPD and about two-thirds of both histologies responded well to the treatment. There 
was no statistical significance of the histological type in the different response group. The 
range TPS Score median was 70% to 90% in all groups (p=0.6). The PD-L1 infiltration in im-
mune cells was markedly lower in patients with PsPr (< 0.6%) compared to other response 
groups (22-29%). In addition, there was only one oncogenic mutation in patients with PsPr. 
3.3 Laboratory parameters and weight 
Laboratory parameters and weight were documented and the median was calculated at baseline 
for each response group: 
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Table 13: Baseline weight, laboratory parameters and tumor size according to response group 
Parameter Level ED OR PsPr RPD SD P-value Test 
N  9 27 6 14 9   
Weight (kg)       0.70 Analysis 
of Vari-
ance 














 Missing 6 4 0 3 0   
CRP (mg/l)       < 0.01 Analysis 
of Vari-
ance 














 missing 3 1 0 0 0   
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Parameter Level ED OR PsPr RPD SD P-value Test 
LDH (U/l)       < 0.01 Analysis 
of Vari-
ance 














 missing 4 1 0 0 0   
GL index       0.17 Analysis 
of Vari-
ance 














 missing 1 1 0 1 0   
Tumor size 
(mm) 




Parameter Level ED OR PsPr RPD SD P-value Test 
 missing 9 0 0 2 0   

















There were six missing weight values in the ED group (n=9), so the calculated median is not 
representative. Median weight for patients with RPD (83) was higher than the other groups (74-
77). The baseline CRP was significantly higher in patients with ED and RPD, with a median of 
136 and 65 respectively compared to other well response groups, median (4.2-7.5) P-value (< 
0.01) according to Analysis of Variance. LDH median was higher in patients with ED (325) than 
in other response groups, the lowest medians were in patients with PsPr and OR (183 and 190) 
P value <0.01 adjusted to (0.03). Regarding G/L index, patients with ED showed the highest 
median (7.1). G/L index differences were not significant among other groups (P value= 1). 
Excluding patients with ED, the highest baseline tumor size median was in patients with RPD 
(75 mm). 
In order to define possible associations between changes in the laboratory parameters and pa-
tient response, we observed variations of different parameter from the baseline value in each 
response group. The variations for each parameter (weight, CRP, LDH and the G/L-Index) 
were calculated according to the Delta formula at days 43 and 106. Thereafter, we integrated the 
RECIST curves into the diagram. RECIST curves describe the change of the tumor size meas-




Figure 4:  Visualization of variations of the potential biomarkers, tumor size and weight over time: The 
relative changes are shown on a log scale. The solid lines connect the median values at each time point. 
The boxplots represent the distribution at each day. From right to left: weight, LDH, tumor size 
(RECIST), CRP and G/L index. The change of tumor size for the group PsPr was extended to 190 
days to show the decrease of tumor size beyond its baseline size. 
As shown in the weight curves, patients with RPD had a weight drop as soon as the treatment 
was started until they reached more than 5% weight loss at day 64. Patients with SD had about 
3% weight loss after day 64. There was a slight weight drop for patients with OR between days 
43 and 106. Patients with PsPr disease always had a stable weight. 
LDH values for patients with RPD increased after initiation of the therapy and ended up with 
an increase of more than 10% at day 106. For the SD group there was an LDH elevation till 
day 43, followed by a drop near the baseline value at day 106. In OR patients, there was a de-
cline until day 43, followed by a stable course. Patients with PsPr showed alternating LDH 
measurements in the whole observation period. 
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Figure 5: Boxplots of variations of the potential biomarkers, tumor size and body weight over time:  
response rate (ORR) on the (x-axis) at baseline (first row), at day 43 (second row) and at day 106 (third 
row). Absolute values are shown at baseline. The Y-axis shows the absolute value at baseline (first row) 
and then the changes relative to baseline (Δ) are shown for days 43 and 106 (second and third row). 
The CRP in OR patients declined continuously and showed variable uneven changes in other 
response groups. G/L index declined in patients with OR and SD with a median almost always 
below the baseline. It rose until day 64 in the PsPr group and declined afterwards below the 
baseline value. Patients with RPD had a remarkable increase in the G/L index until 100% at 
day 106. RACIST curves showed the patients’ response according to the change of tumor size 
at day 43 and 106. The curve was extended to day 190 for patients with PsPr disease to visual-
ize the reduction of tumor size beneath its baseline value. 
Based on the response group: patients with an objective response had a markedly continuous 
drop in the tumor size as well as in GL-Index values over time, and although there were some 
fluctuations in the GL-Index, the median has been always lower than the baseline value. The 
CRP and LDH declined as well. There was no significant change in weight. In patients with 
RPD, tumor size, LDH and GL-Index continued to increase. They also showed a significant 
decrease in their weight until day 63. Patients with SD didn’t show a significant change in tu-
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mor size. GL-Index medians didn’t exceed the baseline value at any point of time. Likewise 
were the other parameters. Patients with pseudo-progressive disease were distinguished 
through the increase in the tumor size until day 43, followed by a continuous regression. GL-
index showed a similar pattern with an increase until day 64 and a rash drop to below the base-
line value afterwards.  
3.4 Prediction of patient response 
We developed a predictor using a two-stage hierarchically structured receiver operating charac-
teristic (ROC) analysis for each variable of our data. In the first stage of the ROC analysis the 
response group RPD was separated from the others. In its second stage,  the response group 
OR was separated from the remaining groups SD and PsPr. In both ROC analyses stages, a 
cutoff corresponding to the Youden index was used. For each of the variables, samples classi-
fied as RPD get zero points, samples classified as SD or PsPr get 1 point, and samples classi-
fied as OR get 2 points. The sum of these points constitutes the overall prediction score.  




2 1 0 
Age (years) < 65.5 65.5 to 79.9 ≥ 79.9 
Gender - Female Male 
Histology  Non-squamous NSCLC - Squamous NSCLC or 
NOS 
Smoking status Current or former smoker  Never smoker 
CRP-BL (mg/l) < 23.4 23.4 to 29.2 ≥ 29.2 
CRP-43 (mg/l) < 11.6 11.6 to 18.5 ≥ 18.5 
ΔCRP (mg/l) < -0.7 -0.1 to -0.7 ≥ -0.1 
LDH-BL (U/l) < 142 142 to 176 ≥ 176 





2 1 0 
ΔLDH (U/l) < -0.1 -0.1 to 0 ≥ 0 
GL index-BL < 3.5 3.5 to 7.2 ≥ 7.2 
GL index -43 < 3.3 3.3 to 4.9 ≥ 4.9 
ΔGL index  < -0.4 -0.4 to 0 ≥ 0 
PD-L1 IC = 0 0 to 0.7 ≥ 0.7 
PD-L1 TPS  = 0.5 0.5 to 0.6 ≥ 0.6 
Tumor size-BL (mm) < 27 27 to 60 ≥ 60 
Tumor size-43 (mm) < 27 27 to 89 ≥ 89 
 Δ Tumor size  (mm) < -0.1 -0.1 to 0.2 ≥ 0.2 
This table shows how to assign scores according to the tested parameter. (Left to right) the first column 
shows the tested parameter. For each a score of 2 is assigned to the sample if the value is smaller than 
the one given in the second column, a score of 1 is assigned if the value falls between the cutoffs given 
in the third column, a score of 0 is assigned of the value is greater or equal to the cutoff given in the 
last column. 43: stands for day 43 (after 3 cycles). BL: baseline value. Δ stands for Delta= (X actual- X 
baseline). CRP: c reactive protein milligram/liter. Kg: kilogram, GL-index: granulocytes/lymphocytes, 
LDH: lactate dehydrogenase units/liter, TPS: tumor proportion score, IC: PD-L1 infiltration in 
immune cells. 
 
The performance of this score was assessed by means of a 10-times repeated stratified 10-fold 
cross-validation (CV). The evaluation was performed using CRP, LDH and G/L index from 
baseline to day 106 (Figure 6). The difference in the assigned scores between the groups has 
been assessed using a linear mixed effects model including the results across all 10 repeats of 
the CV (Figure 7). A classification into RPD vs. the other response groups (non-RPD) was 












Figure 6: Two stages Receiver Operating Characteristic (ROC) based prediction using the laboratory 
parameters (CRP, LDH, and GL-index). Grey lines: ROC curves from each repeated cross validation. 
Black line: consensus ROC curve.  
 
Figure 7: Boxplots demonstrate the distribution of the assigned scores in the treatment response 
groups.  The mean of scores in patients with RPD was significantly lower than the score means in pa-
tients with OR and PsPr. The score difference between RPD and SD was statistically non-significant. P 
values are from a linear mixed effect regression, considering all the data from all repeats.  
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Scores of patients with OR at day 43 were significantly higher than scores for those who be-
long to RPD (p=5x10-6). The p-values of score differences for patients with PsPr and SD 
compared  to those with RPD were (p=0.004) and (p=0.084) respectively. The scores of the 
patients in the test set have been calculated at day 43 (Figure 8). 
 
Figure 8: Predicted scores for each patient (x axis). The assigned score (y axis) at day 43. The total score 
of prediction is represented for each patient individually.  
 
The ROC curve showed a predictor sensitivity of 90% at the best setting. The sensitivity is 
defined as the ability of the predictor to sort out patients who are going to benefit from the 
treatment, i.e., non RPD (= OR, PsPr and SD) from patients with RPD. The following param-
eters (CRP, LDH and G-Index) have shown the best achieved sensitivity compared to other 
score parameters at the same predetermined specificity of 50%. 
The chosen best sensitivity parameters were also included in a previously suggested score (ta-
ble 15) to predict patient response in a pretreated population of patients with metastatic 
NSCLC who received a second-line treatment with nivolumab. We tried to validate this score 
by applying it to our patient population who received a first-line treatment with pembroli-
zumab (figure 9). 
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Table 15: A previously described score to predict treatment response to nivolumab based on 
laboratory parameters and tumor size 
Parameter Score 
2 1 0 
Baseline CRP (mg/l) < 5 5 to 60.4 ≥ 60.4 
Baseline LDH (U/l) < 150 150 to 207 ≥ 207 
Baseline tumor size (mm) < 32 32 to 61 ≥ 61 
ΔCRP (mg/l) < -0.6 -0.6 to -0.2 ≥ -0.2 
Δ LDH (U/l)  < -0.1 -0.1 to 0 ≥ 0 
Δ GL index < -0.3 -0.3 to 0.1 ≥ 0.1 
Δ Tumor size (mm) < -0.1 -0.1 to 0 ≥ 0 
(Schiwitza et al. 2019). Δ demonstrates the difference in value between baseline and after 3 therapy cycles. 
CRP: c reactive protein, GL-index: granulocytes/lymphocytes, LDH: lactate dehydrogenase. 
 
Figure 9: Predicted scores according to Schiwitza Score. For each patient (x axis) the assigned score (y 
axis) at day 43 presented as a bar. Different color codes for different response groups. Four patients 
(one patient with OR and three patients with RPD) were excluded due to missing parameters. 
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Applying the Schiwitza score with a modified cutoff of 3.75 points showed a sensitivity of al-
most 88% with a specificity of 63.6% (figure 10). Only two patients with OR (n=26), one pa-
tient with PsPr (n=6) and two patients with SD (n=9) had false negative predictions with a 
total of five false negatives out of 41. The score had a lower specificity with four false positives 










Figure 10: Receiver Operating Characteristic (ROC) shows the capacity of the pre-trained Schiwitza 
score in predicting treatment response to pembrolizumab. At a cutoff score of 3.75 an area under the 
curve of 88% could be achieved.  
 
3.5 Overall survival 
The overall survival was analyzed via two separate Cox regressions, the first to assess the effect 
of all response groups on the survival time (figure 11) and the second to demonstrate the ef-
fect of the derived predicted scores at day 43 from the cross-validation on patients’ survival 
(figure 12). Kaplan-Meier curves have been created to display these effects. 
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Figure 11: Kaplan-Meier curves show the differences in overall survival in the response groups classi-
fied according to RECIST 1.1 criteria after six therapy cycles : The response groups show significantly 
different survival times.  
 
The overall survival times differed significantly according to treatment response based on the 
RECIST 1.1 criteria applied after six therapy cycles. 50% of patients with RPD died after 13 
weeks of the treatment and only two patients survived after one year (14%) while after one 
year, 66% of patients with OR were still living. The one-year survival probabilities for patients 
with PsPr and SD were 83% and 66% respectively.  
Based on a cutoff point at Youden Index, patients of cross validation were classified into pre-
dicted non-RPD (n=34) and predicted RPD (n=18). The predicted patient groups showed 
significantly different overall survival times in nine of the 10 CV repetitions and a tendency for 
a difference (0.05 < p < 0.1) in one repetition. Figure 12 shows a typical example. Further, the 
difference in overall survival between patients with non-RPD and patients with RPD classified 










Figure 12: Kaplan-Meier curves show the differences in overall survival between predicted treatment 
response groups classified during the cross validation. This figure shows the results from one repetition 
of the CV. Patients with non-RPD according to the classifier showed a significantly higher survival 









Figure 13: Kaplan-Meier curves show the differences in overall survival between the predicted treat-
ment response groups based on the Schiwitza score.  
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4 Discussion 
In this retrospective analysis, we correlated patients’ and disease features to the response to 
pembrolizumab treatment, and we were able to validate a weighted score of response predic-
tion. The mentioned score has been described earlier in a pretreated population of patients 
with advanced NSCLC who received treatment with nivolumab (Schiwitza et al. 2019).  
There are several published studies investigating the effect of patient characteristics or histo-
logical features on patient response to treatment with ICIs in different malignancies. The im-
portance of some factors in the prediction of patients’ outcome, like response rate and overall 
survival, has been reviewed as well. In the following discussion, we are going to compare the 
results of the analysis of our small dataset with the available published data and we will try to 
highlight the significance of the investigated factors in our study. 
4.1 Influence of patients’ characteristics on treatment outcome 
Since lung cancer is a disease of the elderly, a key point is to know if an immunosenescence 
(age-related decline in the immune function) would reduce the efficacy of ICI in elderly pa-
tients. Moreover, it is important to know to what extent older patients tolerate this treatment 
modality, if the incidence of adverse events is higher, and if it consequently results in treatment 
limitation in this group of patients. In our small dataset, the difference between medians of age 
in all response groups was not significant (adjusted p=1) and age didn’t affect the response 
rate. The median of age for patients with RPD was the highest among all groups (80 years). 
Yet, the median for patients with early death (71 years) was not notably higher than the medi-
ans for other good response groups, OR and PsPr (69, 70 years). Of 38% of our patients 
(n=25) aged over 75 years, three died early, eight had RPD and the rest (n=14) (56%) re-
sponded well to the treatment. Less than half of patients (n=4) with ED (n=9) and eight pa-
tients (56%) with RPD (n=14) were older than 75 years.  
In a study level meta-analysis with a total of 5265 patients (ICIs: 2925; controls: 2340) from 
nine randomized clinical trials (RCTs), (Nishijima et al. 2016) compared the difference in over-
all survival (OS) and progression-free survival (PFS) between younger and older patients who 
were treated with ICIs. Subgroups were formed according to ICIs (CTLA-4 mAbs or PD-1 
mAbs) and tumor type, mostly melanoma, but patients with advanced NSCLC were also in-
cluded. No significant difference in improvement of PFS was observed in both younger and 
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older patients in all subgroups at a cutoff of 65 years (p=0.23). The analysis showed survival 
benefits in younger (HR, 0.75; 95% CI, 0.68-0.82) and older (HR, 0.73; 95% CI, 0.62-0.87) 
patients as well, except for a subgroup of patients aged over 75 years and treated with PD-1 
antibodies (patients from four trials). The study group contributed the last finding to the het-
erogeneity of the included nine trials in this analysis and to a possible role of immunosenes-
cence in this subgroup. One of the four trials was CheckMate 017. In this study, patients with 
previously treated advanced squamous NSCLC underwent a treatment with the PD-1 mAbs 
(nivolumab) and docetaxel (as control group). The ORR under nivolumab was 20% versus 9% 
under docetaxel (p=0.008). Overall, survival was significantly higher under nivolumab (9.2 
months) versus 6.0 months with docetaxel (95% CI, 5.1 to 7.3) except for a subgroup of pa-
tients aged over 75 years. It is important to mention that there was also a small subgroup in 
which docetaxel patients had a better performance status than the nivolumab group (Brahmer 
et al. 2015). We should take into consideration that in real clinical practice, older patients with 
marginal performance status get a therapy attempt with ICI maybe more often than with a 
conventional chemotherapy. CheckMate 153 is a community-based safety study of nivolumab 
where 1308 patients were subdivided with an age cutoff of  ≥70. In this study,  patients aged 
over 70 (40%) had a similar six months’ survival (63%; 95% CI, 58–67%) compared to patients 
aged under 70 years (63%; 95% CI, 59–67%). Both groups showed a comparable accepted 
safety profile (Casaluce et al. 2018). In a cohort outside the clinical trial, (Bagley et al. 2017) 
investigated 175 patients with advanced NCSLC, with (25%) of the patients aged over 75. El-
derly patients were not inferior in response rates or overall survival compared to the younger 
group. Poor outcome was associated with bad performance status regardless of age. ECOG PS 
≥ 2 was associated with lower ORR (7.1% vs. 23.3%; OR 0.25, 95% CI 0.07 e 0.88; p¼0.03), 
inferior PFS (median 1.8 vs. 2.3 months; HR 1.9, 95% CI 1.3 e 2.8; p¼0.001), and inferior OS 
(median 3.6 vs. 7.8 months; HR 2.6, 95%CI 1.6 e 4.1; p<0.001). In another group of 275 pa-
tients with advanced NCSLC, a subgroup (14%) aged over 75 with a median age of 81 years 
showed no inferiority in response rate or OS (12.7m vs 15.3m; p = 0.92) (Marrone et al. 2018). 
Male and female patients have different immune responses to different triggers and show vari-
ations among their innate and adaptive immunity (Klein and Flanagan 2016). There is a re-
markable prevalence of autoimmune disorders in females (up to 80%). Such a fact reflects the 
presence of gender-related immunity discrepancies. Factors like sex hormones, X chromo-
some, environmental factors and lifestyle could contribute to this variability (Moroni et al. 
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2012). We tried to investigate if such a difference has implications on patient response to the 
therapy with ICIs. In our data set, there was no significant difference in gender distribution 
among response groups (p=13). The male dominance in response groups PsPr and RPD 
(83.3%, 85.7%) is not significant due to a low number of patients and can be explained by the 
male dominance in our cohort (63%). Conforti and colleagues carried out a meta-analysis on 
11,351 patients from 20 clinical trials. Patients with different malignancies, mostly melanoma 
and NCSLC (3482) (31%), were treated with ICI including pembrolizumab and nivolumab. 
7646 (66%) were males and the rest, 3705 (33%), were females. The pooled overall survival 
HR compared to control groups were 0,72 (95% CI 0,65–0·79), 0,86 (95% CI 0,79–0,93) in 
male and female patients,  respectively (Conforti et al. 2018). This analysis shows that both 
sexes can benefit from ICI therapy, yet with  significance for male patients. In this analysis, the 
authors did not review factors that may contribute to lower female benefits like high tumor 
mutational burdens or lower PDL1 expression (Ulrich and Guibert 2018). One of the included 
trials in the Conforti analysis was the KEYNOTE-024, in which 305 patients with advanced 
NSCLC were subdivided into two arms: pembrolizumab (154) and platinum-based chemother-
apy (151). The subgroup analysis favored male patients (n=187) with a HR of death of 0.54 
(0.36 to 0.79) over 0.95 (0.56 to 1.62) for female patients (n=118) (Reck et al. 2016b). Sub-
group analyses in the KEYNOTE-024 included patients from both study arms. Part of the 
female subgroup received a platinum-based chemotherapy. The findings in Wu and colleagues’ 
meta-analysis (n=6096) from 11 trials, CTLA-4 or PD-1 inhibitors (n=3584) versus chemo-
therapies or other therapies (n=2512), NSCLC (2192), are consistent with the Conforti analy-
sis. A better OS was observed in males (HR, 0.62; 95% CI, 0.53-0.71; p<0.001) treated with 
ICI versus controls than females (HR, 0.74; 95% CI, 0.65-0.84; p<0.001). In this analysis, sex 
had more implication for the OS among melanoma patients more than in NSCLC group (Wu 
et al. 2018). The last and largest meta-analysis was from Grassadonia and colleagues: 21 trials 
(n=12,635). They found that ICIs reduced the risk of death for all patients, males and females 
(HR 0.73, p < 0.001 and HR 0.77, p < 0.001, respectively). The results were similar for anti-
PD1 and anti-PDL-1 even when the NSCLC subgroup was considered separately (HR 0.73, 
95% CI 0.63–0.84, p < 0.001 for men and HR 0.66, 95% CI 0.48–0.91, p = 0.011 for women). 
In contrast, the anti-CTLA-4 treatment was effective in men (HR 0.77, 95% CI 0.63–0.94, p = 
0.012), but not in women (HR 0.89, 95% CI 0.76–1.05, p = 0.162). Anti-CTLA-4A showed 
benefits in both sexes only when it was restricted to melanoma (HR 0.67, 95% CI 0.50–0.90, p 
= 0.008 and HR 0.80, 95% CI 0.68–0.94, p = 0.006, respectively) (Grassadonia et al.). 
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To examine the implication of tobacco consumption on the outcome of ICIs treatment we 
stratified the data from smoking status to all response groups. The number of smokers was 
higher in all good response groups, (100%) in SD and PsPr, (92.6%) in OR, than patients with 
ED (88.9%) or RPD (85.7%). The highest number of current smokers was in PsPr patients 
(66.7%) followed by OR and SD (55.6% for each). Current smokers were (35.7%) of RPD and 
least in ED (33.3%). We defined current smoking as ongoing tobacco consumption until time 
of first diagnosis. In our predictor ever smokers get (2 points) versus (zero points) for never 
smokers, so smoking is a positive outcome predictor.  After all, no conclusion can be drawn 
from this data as we didn’t control the smoking status through the whole therapy period and 
due to the small data set we have, the data did not show a statistical significance between 
smokers and non-smokers (p= 0.70). 
For the same purpose Bingjia Li and colleagues carried out a meta-analysis on 1981 patients 
with NSCLC from four phase III clinical trials (ICIs vs. chemotherapy). ICIs were exclusively 
PD-1/PD-L1 inhibitors: nivolumab (n=826), pembrolizumab (n=305), and atezolizumab (n = 
850). Never smokers were (n=298), former or current smokers (1683). Programmed cell death 
inhibitors increased the OS (HR, 0.69; 95% CI, 0.60–0.78) and PFS (HR, 0.55; 95% CI, 0.43–
0.67; p = 0.027) in smoking patients versus chemotherapy and no significant improvement in 
OS (HR, 0.8; 95% CI, 0.54–1.06; p > 0.05) or PFS (HR, 0.90; 95% CI, 0.11–7.59; p = 0.637) 
was observed in non-smoking patients with anti-PD-1 immunotherapy compared with chemo-
therapy. The authors contributed the results to possible gene mutations and molecular differ-
ences in smokers (Li et al. 2018). A review of nine clinical trials done by (Norum and Nieder 
2018) showed that smoker NSCLC patients have higher PD-L1 TPS scores and better re-
sponse rates than never smokers. Furthermore, one study revealed higher mutational burdens 
in smokers. Two of the reviewed studies showed no significant difference. Another meta-
analysis (Kim et al. 2017b) included (2389) ever smokers and (413) never smokers with 
NSCLC treated with ICIs versus chemotherapy. The results are consistent with Bingjia Li anal-
ysis; ICIs significantly prolonged OS compared with chemotherapy in ever smokers (HR = 
0.70 [95% CI, 0.63–0.79], p < 0.00001) but not for never smokers (HR = 0.79 [95% CI, 0.59–
1.06], p = 0.12) and the authors concluded that smoking status may be a positive predictive 
factor for survival benefits under ICIs. 
Desrichard and his study group analyzed tobacco-associated mutational burdens in DNA and 
RNA sequencing data sets from subjects with lung squamous cell carcinoma LUSC (n=205) 
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and head and neck squamous cell carcinoma HNSC (n=423). They described an increase in 
smoking-induced mutational burdens in the tumor microenvironment of both groups. The 
authors found that these mutations have direct immunosuppressive effects including lower 
levels of immune infiltration, cytolytic activity, and interferon-γ pathway signaling in the 
HNSC group, while the effect was completely the opposite with an increase of the inflamma-
tory tone in the tumor microenvironment in the LUSC group (Desrichard et al. 2018). In this 
study there was no data about T cell load or PD-L1 expression in the tumor microenviron-
ment in the specimens of the included subjects. 
4.2 Importance of tumor histological features and mutational analysis 
In our small cohort there were no preferences among response rate depending on the main 
histological type. About 65% of patients with squamous histology (n=13/20) and 64% of ade-
nocarcinoma patients (n=27/42) responded well to the therapy. To the best of our knowledge 
there is no published clinical data that favors one of the NSCLC histological subtypes either in 
response rate or OS under treatment with ICI. In the pivotal trial (Checkmate 024) patients 
with squamous (18.8%) and non-squamous NSCLC (81.8%) benefitted from pembrolizumab 
treatment. The HR of disease progression or death in patients with squamous NSCLC under 
ICI versus chemotherapy 0.35 (95% CI, 0.17-0.71) was comparable to the adenocarcinoma 
subgroup 0.55 (95% CI 0.39 0.76) (Reck et al. 2016a). A similar result was also observed in the 
outcome of adding pembrolizumab to chemotherapy in both squamous and nonsquamous 
NSCLC. In the (KEYNOTE-189) study, a total of 616 patients with nonsquamous NSCLC 
were randomly assigned to the pembrolizumab/pemetrexed/carboplatin combination group 
(n= 410) and the placebo/same chemotherapy combination group (n=206). The median PFS 
was 8.8 months (95% CI, 7.6 to 9.2) in the pembrolizumab-combination group versus 4.9 
months (95% CI, 4.7 to 5.5) in the placebo-combination group (hazard ratio for disease pro-
gression or death, 0.52 (95% CI, 0.43 to 0.64; p<0.001) (Gandhi et al. 2018). In another phase 
III clinical trial, a total of 559 patients with squamous NSCLC were randomized in a 1:1 ratio 
to pembrolizumab/paclitaxel/carboplatin and placebo/ same chemotherapy study arms. The 
median PFS was 6.4 months (95% CI, 6.2 to 8.3) in the pembrolizumab-combination group 
and 4.8 months (95% CI, 4.3 to 5.7) in the placebo-combination group (hazard ratio for dis-
ease progression or death, 0.56 (95% CI, 0.45 to 0.70; p<0.001) (Paz-Ares et al. 2018). 
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We hypothesized that the response rate correlates proportionally to the PD-L1 expression rate. 
In our data set, the medians of PD-L1 expression on tumor cells ranged between 70% and 
90%. The same applies for PD-L1 expression on immune cells. The medians PD-L1 IC were 
between 18% and 28% except for PsPr (<1%). Due to the low patient numbers in each of the 
subgroups we could not observe a significant difference between the PD-L1 medians among 
all response groups (adjusted p=1). The effect of PD-L1 expression on patients’ outcomes has 
been reviewed in many studies. The effect of TPS on patients’ OS was very well demonstrated 
in the phase III clinical trial (KEYNOTE-042, published in April 2019). The median OS in 
patients with NSCLC (n=1274) treated with pembrolizumab monotherapy (n=637) versus 
platinum-based chemotherapy (n=637) with TPS ≥50% , ≥20 and ≥1%, were 20·0 months 
(95% CI 15·4–24·9) for pembrolizumab versus 12·2 months (10·4–14·2) for chemotherapy, 
17·7 months (15·3–22·1) versus 13·0 months (11·6–15·3), and 16·7 months (13·9–19·7) ver-
sus 12·1 months (11·3–13·3), respectively (Mok et al. 2019). A retrospective data analysis of 
112 patients with NSCLC under pembrolizumab treatment showed that patients with higher 
TPS experience better response rates, PFS and OS. The patient cohort was homogenous, i.e., 
no significant differences in age, sex, histology, smoking status or oncogenic mutations. The 
cohort was divided to two subgroups: patients with PD-L1 TPS of 50-74% (N = 44), and TPS 
of 75-100% (N = 68). Patients with TPS 75-100% had a significantly higher ORR (47.1% vs 
13.6%, P < 0.01), significantly longer median PFS (5.1 months [95% CI: 1.8-4.5] vs 2.5 months 
[95% CI: 3.8-7.4], p = 0.02), and higher 12-month OS (76.4% vs 54.4%) compared to patients 
with TPS 50%-74% (Jimenez Aguilar et al. 2018). Corresponding results were also observed in 
many others trials under different ICI; a better response rate was demonstrated in patients with 
higher TPS in the treatment with nivolumab plus ipilimumab as the first line for advanced 
NSCLC (Hellmann et al. 2017) and under atezolizumab versus docetaxel in previously treated 
NSCLC (OAK trial) (Rittmeyer et al. 2017). The effect of the PD-L1 expression on immune 
cells was not always in the focus of many clinical trials. However, the increase of PD-L1IC 
showed ORR benefits in the OAK (Rittmeyer et al. 2017) and the phase 2 POPLAR trial for 
atezolizumab (Fehrenbacher et al. 2016). 
The generated score from our small data set showed, according to the two-stage ROC analysis, 
a negative effect of the PD-L1 expression on the ORR. This heterogenic statistical finding is 
explained with the slightly elevated TPS in patients with ED (90%) and RPD (80%) and with 
the small patient numbers in all subgroups. This finding has shown no statistical significance 
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and was ignored as we validated the Schiwitza score on our cohort. Particularly, it was incon-
sistent with the available published data from different, large clinical trials. 
KRAS mutation is the most common, known oncogenic alteration in NSCLC and occurs in 
20%-40% of lung adenocarcinoma with a prevalence in Western vs Asian population (26% vs. 
11%) and in smokers vs never smokers (30% vs. 10%). Some preclinical and clinical trials sug-
gest that KRAS mutation may have implications on patient outcomes under ICI treatment, 
especially when it coexists with other oncogene mutations like TP53  (Adderley et al. 2019). 
We tested all patients with nonsquamous and one patient with squamous histology (n=46) for 
KRAS, TP53 and MET mutations. Nineteen patients (41%) proved to have at least one KRAS 
or TP53 mutation, and six patients (13%) had MET mutation. KRAS and TP53 mutations 
coexisted in nine patients: four OR, three ED, one RPD and one stable disease. For patients 
with OR mutated KRAS, the wild-type phenotype ratio was 1:1. 
Ten patients with mTP53 responded well to the treatment versus nine patients with ED or 
RPD. In our data set there was no remarkable effect of oncogenic mutations on response rate. 
We compared our results to the available clinical data. A retrospective analysis of 282 patients 
with NSCLC (all histological subgroups) treated with 13 different ICIs (about 88% of the pa-
tients treated with nivolumab), in different treatment lines (about 53%  2nd line, 24% 1st line 
and 24% 3rd line), including 162 (57.4%) with KRAS mutation, 27 (9.6%) with other mutations, 
and 93 (33%) with a wild-type phenotype. KRAS mutation did not show any predictive effica-
cy in ORR, OS or PFS (Jeanson et al. 2019). In another study, 138 patients with a KRAS mu-
tant NSCLC and 371 with a KRAS wild-type tumor from three clinical studies were included 
in a meta-analysis. All patients were treated with atezolizumab in the second or third line. 
Compared to chemotherapy with docetaxel, atezolizumab improved OS in patients with KRAS 
mutant NSCLC (hazard ratio = 0.64 [95% confidence interval, 0.43-0.96], p = 0.03). For pa-
tients with KRAS wild-type NSCLC, atezolizumab did not improve the OS over that with 
docetaxel (hazard ratio = 0.88 [95% confidence interval, 0.68-1.13], p = 0.30) (Kim et al. 
2017a). The inconsistency between the available clinical data about the predictive role of onco-
genic mutations under ICI treatment may be due to the presence of many other influencing 
factors in the study groups that contribute to the prediction of patients’ outcomes. The predic-
tive efficacy of mutant oncogene under ICI treatment stays controversial. 
 
Discussion 59 
4.3 Efficacy of serum biomarkers as predictors of treatment outcome 
C- reactive protein is an important tumor marker with a great prognostic value. A retrospective 
analysis for data of about 5000 patients with different solid tumors demonstrated that high 
CPR was associated with a statistically and clinically higher risk of death (Shrotriya et al. 2018). 
Despite the fact that CRP is a nonspecific inflammatory marker, it certainly proved to have an 
important prognostic value in solid tumors in several clinical trials (Shrotriya et al. 2015). A 
meta-analysis of eight clinical studies exclusively included 1668 NSCLC patients, and clarified 
that CRP is an independent prognostic factor for patients with NSCLC and that elevated CRP 
levels may predict a poor five-year overall survival (Jing et al. 2015). A retrospective data analy-
sis of 124 NSCLC patients treated with nivolumab concluded that the ORR in patients with 
elevated CRP levels was significantly worse than those with normal CRP levels (cutoff= 1 
mg/dl) (8.3 vs 23.4%, p = 0.0180). The same study demonstrated that elevated LDH levels 
were significantly associated with a shorter PFS and OS as well (Oya et al. 2017). Lactate dehy-
drogenase is an essential serological tumor marker as it correlates with tumor burdens (Buder-
Bakhaya and Hassel 2018). LDH was included in the American joint committee on cancer as a 
staging criterion for melanoma and is still considered as an important survival predictor in 
melanoma patients (Gershenwald et al. 2017). In advanced NSCLC a clinical data analysis of a 
total of 394 patients suggested that the LDH level at baseline (time of patient’s presentation) 
correlates proportionally with the extent of whole body metastases and is a modest, independ-
ent predictor of OS in stage IV NSCLC (Lee et al. 2016). In our data analysis, the medians of 
baseline CRP serum level were significantly higher in patients with ED (136 mg/L) and RPD 
(65 mg/L) versus (7.5, 5.7, 4.2 mg/L) in patients with OR, PsPr and SD respectively, (p= < 
0.01). A baseline CRP value (>29.2 mg/L) was a negative predictor in our score according to 
the trained ROC analysis. A decline in the CRP level at day 43 for more than 10% associated 
with a better response versus a negative prediction value when the decline was less than 7%. 
The median LDH at baseline was significantly higher in ED (325u/l) and RPD (224u/l) com-
pared to OR (190u/l), PsPr (183u/l) as well (p= < 0.01). A baseline LDH (>195u/l) or a con-
stant increased LDH at day 43 were negative predictors. A decline of the LDH >10% at day 
43 was associated with a better response. The prognostic importance of G/L index in solid 
tumors and NSCLC has been clarified in several clinical studies. In a clinical data analysis of 
138 NSCLC patients at G/L index cutoff of (<3.24 or ≥3.24), the calculated median overall 
survival was 37.0 (95% CI 17.5-56.5) months in the group with a low G/L index versus 10.0 
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(95%CI 5.0-15.0) months in the group with a high NLR (p<0.0001) (Kos et al. 2015). In our 
data set a remarkable, elevated G/L index at baseline was noticed in ED (7.1) versus all other 
response groups (2.1-4.7), (p=0.17). Despite the statistical insignificance at baseline, a signifi-
cant difference was noticed during the treatment, particularly at day 106 where the median of 
G/L index values in the RPD group was about 100% more than the baseline value, while the 
medians of all good response groups declined beyond the baseline line. A decline in the G/L 
index of more than 10% was associated with a better response in the ROC analysis. 
To demonstrate the significance of these serum biomarkers we tested the previously men-
tioned ‘’Schiwitza score’’, which combined all the three serum biomarkers, on our cohort. The 
score showed a prediction sensitivity of almost 88% with a specificity of about 64%. The score 
one-year survival prediction showed a statistical significance (p= 0.00089) in survival probabil-
ity between the predicted groups. The one-year survival probability of predicted non-RPD was 
64% compared to 69% in reality. The predicted survival probability in predicted RPD was 42% 
versus 14% in reality. The discrepancy in one-year survival between predicted RPD (42%) and 
real RPD (14%) is due to the score’s low specificity (63%) as five patients were false negatively 
predicted as RPD. 
4.4 Molecular escape mechanisms under ICI 
Patients respond differently to treatment with immune checkpoint inhibitors. They differ in 
the initial response to the treatment, some responding well from the beginning (responders), 
others failing to show any initial response (innate resistant) and some developing resistance 
after a temporal response (acquired resistance). Some patients show discrepancy in the re-
sponse between two targeted lesions of the same disease (Jenkins et al. 2018). There are many 
extrinsic and intrinsic factors contributing to such diversity. Tumors could be classified into 
hot and cold tumors depending on the degree of antigen presentation by immune cells that 
infiltrate the tumor microenvironment. This has a crucial impact on a patient’s response to ICI 
(Ramos et al. 2017). A primary innate resistance to ICI may result from extrinsic factors like 
insufficient tumor-specific antigen presentation, poor tumor immunogenicity or inadequate 
maturation of antigen-presenting cells, and inadequate T cells priming, or due to increased 
release of inhibitory cytokines in a tumor microenvironment (O’Donnell et al. 2016; Gide et al. 
2018). Other intrinsic factors involve genetic alteration and intrinsic pathway modulation that 
affect specific antigen presentation or interaction with immune cells in a tumor microenviron-
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ment. For example, a mitogen-activated protein kinase (MAPK) signaling pathway results in an 
increase of VEGF and IL-8 secretion and their down-regulatory effect on a T cell. Another 
important intrinsic resistance mechanism is the mutation of Janus kinase (JAK1/2) which is 
essential to the gamma interferon signaling pathways. This results in a decrease of IFN γ ca-
pacity in MHC up regulation and the recruitment of T cells (Sharma et al. 2017). Genetic muta-
tions may also result in low specific antigens presentation, increased expression of PD-L1-like 
molecules (Jenkins et al. 2018). Sade Feldman and colleagues observed mutations in beta-2-
microglobulin (B2M), an essential component of MHC class I antigen presentation in 29.4% of 
patients with progressive melanoma treated by checkpoints inhibitors (Sade-Feldman et al. 
2017). 
4.5 Pseudoprogression 
This phenomenon has been observed in tumors under targeted therapies including immuno-
therapies and ICI. It describes an initial increase in tumor mass size due to inflammatory cell 
infiltration and edema associated with the desired immune response, which eventually resolve 
and uncover a responsive tumor mass. This early false finding as a specific response pattern 
under targeted therapies led to modifications in tumor response evaluation criteria under con-
ventional therapy such as RECIST (Response Evaluation Criteria in Solid Tumors) (Chiou and 
Burotto 2015). Pseudoprogression is the increase of tumor burden or formation of new lesions 
after 12 weeks of treatment. In this case a radiological assessment is not enough to confirm a 
progressive disease depending on Immune-related Response Criteria (irRC) (Ozaki et al. 2017). 
A new histological examination is gold standard to confirm the diagnosis (Ranjan et al. 2018). 
In most cases a delayed good response (decrease of tumor size) that can be observed in later 
radiological assessments is enough to confirm the diagnosis. The patient clinical status during 




This study has several limitations. First, it is a monocentric retrospective analysis which offers 
an inferior level of evidence compared to prospective studies. This limitation involves the ret-
rospective evaluation of patients' response to the treatment with pembrolizumab and the sub-
jective assessment by physicians concerning the time of therapy termination due to disease 
progression. Another study limitation is the small number of the included subjects, particularly, 
in patients with pseudoprogression; however, pseudoprogression is a relatively uncommon 
phenomenon to observe under treatment with ICIs. Finally, our study included only patients 
with previously untreated NSCLC who received a first-line treatment with the ICI pembroli-
zumab. Prospective larger cohort studies on patients with different ICI agents and subsequent 




In a retrospective analysis, we studied the relationship between treatment response to a first-
line therapy with pembrolizumab and several clinical factors like age, gender, smoking status 
and tumor histology features in patients with advanced NSCLC. Further, we were able to vali-
date a previously suggested score to predict treatment response to ICIs after only three therapy 
cycles by combining laboratory parameters (LDH, CRP and the GL-index) and tumor size 
derived from CT-imaging. Furthermore, we studied the capacity of the suggested score in pre-
dicting the overall survival.  
As there is no indisputable single clinical variable or biomarker to predict patient response to 
the treatment with ICIs, a weighted score entails the routinely collected laboratory parameters 
and tumor size might be a helpful tool in early predicting the long-term response to a treat-
ment with pembrolizumab, especially, as during treatment with ICIs a so-called pseudopro-
gression is hard to distinguish from a real progressive disease. 
In patients with advanced NSCLC, a score combining the routinely collected clinical variables 
might enable an early prediction of treatment response to ICIs. A prospective validation of our 
results in larger cohorts is necessary before firm conclusions affecting patient care can be 
drawn. 
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5 Abstract  
Lung cancer is one of the most frequently occurring malignancies at the present time and still 
the leading cause of cancer deaths worldwide. Checkpoint pathway inhibitors are a family of 
cancer immunotherapy that has been shown to improve disease progression-free survival as 
well as overall survival in patients with advanced NSCLC.  
In this retrospective study, we analyzed data of 66 consecutive patients with metastatic NSCLC 
who received pembrolizumab as a first-line monotherapy. We attempted to validate and im-
prove the reliability of a previously described score of treatment response prediction. The 
score entails various laboratory values (LDH, CRP and granulocyte/lymphocyte ratio) as well 
as the change in tumor size derived by CT imaging. Further, we investigated other clinical, 
radiological and pathological characteristics and correlated them to patients’ response to the 
treatment with pembrolizumab.  
Aiming to examine the possibility of the prediction of patients’ response, we applied the pre-
diction score to our cohort of patients after three cycles of the treatment, and as a result, we 
classified them according to the score into four predicted response groups: stable disease, ob-
jective response, pseudoprogressive and real progressive disease. We examined the reliability of 
this prediction comparing the score results to patients’ real response, which was defined based 
on the RECIST 1.1 criteria. The prediction score showed a prediction sensitivity of almost 
88% with a specificity of about 64%. Sensitivity was defined as the ability of the predictor to 
sort out patients who are going to benefit from the treatment, i.e., non RPD (= OR, PsPr and 
SD), from patients with RPD. Furthermore, we validated the score by testing the possibility to 
predict patients’ survival probability, the predicted one-year survival showed a statistical signif-
icance (p= 0.00089) in survival probability between the predicted groups. The one-year surviv-
al probability of predicted non-RPD was 64% compared to 69% in reality.  
As there is no indisputable test to predict patient response to treatment with immune check 
point inhibitors (ICIs), a score could be a helpful tool in monitoring patients under treatment 
with ICIs, especially, as during treatment with ICIs a so-called pseudoprogression is hard to 
distinguish from a real progressive disease. A prospective validation of the concluded results 




Table A1: Absolute values of C - reactive protein (mg/L) 
Patient’s 
Number  
Day 1 Day 22 Day 43 64 85 106 
1 10.7 56.3 13.4 3.8 18.5 4 
2 137 124 189 116   
3 85.2 90.2 104.9    
4 36.9 33.9 33.1 43.7 55.6 66.3 
5 196.8 84 40.6 207 65.2 178.3 
6 5.4 2.9 8.4 5.4 15.3 4.3 
7 61 4.3 3.4 4.4 3.6 3.3 
8 3.2 3.7 3.5 4 14.3 3.6 
9 11.9 23.2     
10 3.1 3.6 3.4 3.4 3.3 3.4 
11 159 178 189    
12 3.9 3.9 17.4 3.5 0.3 4.5 
13 118 3.3 3.3 16.1   
14 3.3 3.3 3.4 3.3 9.6 16.1 
15 7.9 8.3 15.8 10.5 3.3 15.4 
16 3.2 3.6     
17 5.9 4.8 4.8 4.4 4 2.7 
18 98 53.7 55.9 39.7 36.4 49.7 
19 31 44.4 69.2 30.6   
20 6 9.8 17.9 11.6 7.3 13.6 




Day 1 Day 22 Day 43 64 85 106 
22 11.6 14.7 55.4 35.7 7 3.8 
23 3.3 6.9 3.1 3.8 60.8 35.6 
24 98.1 133.5     
25 26 38 10.2 8.6 18.7 34.3 
26 4.8 3.3 3.7 3.6 3.6 3.5 
27 196 138 111 73.9 51.1 57.8 
28 3.3 3 3.2 3.3 11.4 14.4 
29 5.4 15.7 9.1 6.8 4.2 3.5 
30 15.8 41.3 43.3 78.8 60.5 51.7 
31 154.5      
32 3.8 24.7 25.2 29.7 15.7 21.3 
33 70.9 31.6 90.4 32.5 9 3.8 
34 3.3 3.3 1.4   19 
35 4.2 16.9 9.1 4.6  32 
36 3.8 4.3 4.7 3.9 3.1 2.8 
37 42 198.5 267.8    
38 19.6 3.9 3.8 3.8 5.8 8.7 
39 3.8 4.1 6.1 79 63.8 54.3 
40 4.6 4.1 4.5 14.1 14.6 16.8 
41 5.6 3.7 9.9 3.7 4.1 16.1 
42 39.2 57.9     
43 19.1 15.7 17.3 48.8 5.3 3.7 




Day 1 Day 22 Day 43 64 85 106 
45 31.5 14 4.1 4.7 2.7 8.5 
46 59.3 114.6 38.9 10.7 3.7 4.4 
47 4.3 3.7 2.3 2.4 3.5 3.7 
48 63.2 21 48.9 199.3 152.5 28.4 
49 47.2 77.3 83.9 88.4 21.6 13.8 
50       
51 105.1 186.1 117.5 127.2   
52 67.7 30.5 32.5 31.3 138.2  
53  164     
54 190      
55 173      
56       
57 62 61.3 6.2 9.4 26.6 11.3 
58 79.4 4 4.5   6.7 
59 23.4  71.8   22.1 
60 148.1  110.5   4.2 
61 15.5  90.2   4.4 
62 7  5.7   7.8 
63 4.5  4.5   4.7 
64 45.8  46   4.2 
65 29.2  16.9   197.5 
66       
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Table A2: Absolute values of lactate dehydrogenase (U/L) 
Patient’s 
number  
Day 1 Day 22 Day 43 Day 64 Day 85 Day 106 
1 185  192 191 185 184 
2 142 290 372 272   
3 168 145 183 143   
4 149 159 157 149 186 153 
5 239 190 217 195 184 317 
6 179 179 193 193 207 207 
7 165  185 168 165 161 
8 282 257 296 261 296 301 
9 278 411     
10 226 181 218 267 157 218 
11 271 209 308    
12 289 211 232 210   
13 181      
14 134 223 186 184 186 174 
15 246 278 239 232 245 273 
16 652 298     
17 202 188 167 171 172 173 
18 310 311 325 303 301 285 
19 246 250 242 233 225 223 
20 204 213 196 202 213 225 
21 280 260 226 236 265 251 




Day 1 Day 22 Day 43 Day 64 Day 85 Day 106 
23 277 237 176 154 156 181 
24 295      
25 257 336 271 272 246 264 
26 151 144 130 120 131 131 
27 523 594 689 466 368 323 
28 177 168 173 168 178 171 
29 176 160 169 200 172 195 
30 171 177 174 168 179 186 
31 325      
32 152 158 196 215 206 190 
33 268 227 175 232 351 329 
34 213 177 190   201 
35 146 150 152 166   
36 203 195 203 197 189 246 
37 223 477 1074    
38 324 388 271 292 245 277 
39 183 186 184 205 187 182 
40 176 179 165 174 180 234 
41 171 167 165 172 143 169 
42 695      
43 357 384 357 319 437 447 
44 182 209 192 175 150 169 




Day 1 Day 22 Day 43 Day 64 Day 85 Day 106 
46 182 185 193 195 164 188 
47 164 150 155 174 163 167 
48 226 245 240 205 709 660 
49 164 175 200 215 176 189 
50       
51 155 274 631    
52 278 258 260 280 277  
53  346     
54 344      
55  271     
56       
57 99 108 108 118 137 120 
58 104  113   4.2 
59 184  153   166 
60 288  149   155 
61 212  202   156 
62 188  187   201 
63 241  221   200 
64 230  275   266 
65 283  292   399 




Table A3: Absolute values of granulocytes/ lymphocytes index  
Patient’s 
number  
Day 1 Day 22 Day 43 Day 64 Day 85 Day 106 
1 1.2096 2.4057 2.6818 1.3422 1.625 1.3059 
2 11.879 139.906 12 171.339 93.384  
3 5.7692 7.4732 9.60975 6.7786 8.3252  
4 7.212121 7.81481
4 
8.64367 8.35632 10.2876 10.21176 
5 4.05673 3.6242 2.5079 5.21259 79.23 52.13 
6 2.4647 2.2528 2.640522 2.1265 2.69753 3.1265 
7 12.5327 3.5037 2.7723 3.0731 5.3603 2.2953 
8 3.5126 4.6071 4.8085 4.7731 4.75 4.2277 
9 4.0657 7.9573 3.781 2.994 3.7214 3.564 
10 3.9506 5.5896 3.8333 3.1978 2.9948 3.7214 
11 9.4188 20.8425 24.93    
12 5.3873 4.3627 5.4444 23.9516 3.7862 4.4607 
13       
14 5.4898 2.2662 19 2.5026 1.7012 2.9025 
15 3.3068 1.4866 3.8346 2.7716 3.1219 3.4973 
16 4.3522 5.532     
17 2.8292 2.7622 23 2.1169 1.6348 1.482 
18 13.1772 6.4418 9.3 10.3578 7.5648 6.8016 
19 4 7.5806 3    
20 1.6796 1.6299 2 2.4201 2.0434 2.5669 
21 3.7421 3.9075 3 3.4629 3.5873 3.8141 
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22 4.4347 8.5037 9.7 4.0397 3.8705 8.3984 
23 8.031 5.8429 2.2527 2.1726 32.204 8.0078 
24 3.914 5.006     
25 4.673 5.9354 3.0588 4.017 3.3458 4.017 
26 2.6373 2.6272 1.6262 1.9509 1.4272 1.275 
27 11.6956 4.0666 3.0685 1.5015 1.875 1.8965 
28 3.7279 5.5664 2.4055 2.5449 3.3065 2.9602 
29 0.5957 0.7949 1.0402 0.8153 0.7967 0.6157 
30 11.6046 8.5641 6.2021 6.5402 16.75 9.1803 
31 6.691 13.942     
32 5.4 3.7718 2.7486 2.9052 2.6859 3.0042 
33 6.3115 5.5208 4.2421 2.8321 4.7142 3.6518 
34 1.816 2.148 1.99   1.592 
35 2.357 2.145 2.9067    
36 4.881 4.416 2.674 4.294 2.589 2.328 
37 53.516 14.644 16.913    
38 7.077 4.879 3.637 6.438 3.623 5.034 
39 5.228 5.736 9.091 8.078 8.693 10.229 
40 3.485 2.062 1.764 2.132 2.456 2.68 
41 3.502 6.3 4.22 4.177 2.043 3.367 
42 59.7719      
43 1.683 1.385 1.637 2.748 3.039 1.146 
44 3.755 19.189 7.276 3.484 5.506 1.928 
45 5.759 5.841 8.341 1.952 3.34 1.777 
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46 6.33 6.406 21.541 12.467 4.117 3.666 
47 3,296 4.34 3.835 4.685 4.415 5.431 
48 2.317 5.585 2.418 13.779 5.915 5.303 
49 9.827 8.6 11 7.878 8.678 4.88 
50 6.84      
51 2.623 3.418 6.32 6.308 2.973 4.891 
52 2.375 3.397 2.533 2.458 2.5 6.026 
53 9.31 7.828     
54 6.17 5.81     
55 8.933 23.56     
56 7.35      
57 13.52  0.925   5.1 
58 2.626  1.815   2.585 
59 2.482  1.62   2.223 
60 8.807  6.091   2.843 
61 2.788  2.86    
62 2.343  1.408   0.326 
63 3.674  3   2.889 
64 8.187  4.771   4.023 
65       




Table A4: Absolute values of tumor size in millimeters  
Patient’s number  Baseline  Day 43 Day 106 Day 190 
34 46 68 33 22 
36 18 12 11  
57 66 35 23  
6 25 12 10 8 
47 31 11 6 3 
60 87 33 15  
38 95 42 30 22 
12 57 40 25 21 
14 124 82 65 57 
22 70 51 42 39 
23 57 32 26  
26 65 26 18 17 
28 22 10 6  
41 61 38 25 24 
45 75 31 29 41 
44 47 13 8  
7 23 18 10 8 
15 86 72 31 22 
62 57 45 39  
17 82 66 34  
43 89 76 42 40 
58 67 47 29  
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Patient’s number  Baseline  Day 43 Day 106 Day 190 
32 89 67 62 61 
30 60 24 19 18 
61 44 25 17  
63 44 0 0  
64 104 105 61  
40 36 37 48 25 
29 27 42 18 13 
59 80 109 89  
46 74 90 69 50 
20 41 50 51 31 
2 168 206   
51 60 117   
4 65 89 101  
5 88 156   
11 45 69   
48 19 33   
1 71 62 100  
3 86 131   
37 46 70   
49 79 111   
52 108 150   
65     
8 55 27 60 62 
Appendix 76 
Patient’s number  Baseline  Day 43 Day 106 Day 190 
10 38 29 31  
18 68 66 69 67 
21 95 92 93  
25 49 36 42  
39 40 41 41 40 
27 112 115 108 109 
33 138 137   
35 52 48   
66 38 13 7  
Table A5: Survival in days and response  
Patient’s number  survival in days  Patient’s response 
40 459 PsPr 
59 356 PsPr 
46 479 PsPr 
20 576 PsPr 
29 757 PsPr 
34 666 PsPr 
1 337 RPD 
2 92 RPD 
3 73 RPD 
24 125 RPD 
37 45 RPD 
65 168 RPD 
Appendix 77 
Patient’s number  survival in days  Patient’s response 
48 96 RPD 
49 415 RPD 
11 35 RPD 
19 614 RPD 
51 88 RPD 
52 51 RPD 
4 169 RPD 
5 127 RPD 
6 625 OR 
7 660 OR 
47 423 OR 
60 337 OR 
38 492 OR 
12 549 OR 
61 308 OR 
14 530 OR 
36 232 OR 
15 574 OR 
57 391 OR 
62 321 OR 
17 350 OR 
63 310 OR 
22 686 OR 
Appendix 78 
Patient’s number  survival in days  Patient’s response 
23 174 OR 
64 301 OR 
26 510 OR 
28 608 OR 
41 497 OR 
30 501 OR 
43 437 OR 
32 424 OR 
45 367 OR 
58 359 OR 
44 448 OR 
66 609 OR 
33 645 SD 
25 209 SD 
27 345 SD 
8 610 SD 
10 253 SD 
39 502 SD 
18 468 SD 
21 632 SD 
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